
A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic  Androgen-Independent Prostate Cancer(https://clinicaltrials.gov/show/NCT00090545)
 ,First Stage - Disease Progression,Second Stage - Increased Accrual
 ,The first stage was to rule out the probability of 4 month progression free survival. Patients were given 400 mg BAY 43-9006 orally twice daily in 28 day cycles.,Due to prostatic specific antigen and radiographic discordance during the first stage the protocol was amended to allow accrual to a second stage. 400 mg BAY 43-9006 orally twice daily in 28 day cycles.
Total all-cause mortality,0/22 %0.0,1/24 %4.17
Total serious adverse events,2/22 %9.09,6/24 %25.0
Constipation,0/22 %0.0,1/24 %4.17
Dehydration,0/22 %0.0,1/24 %4.17
Death not associated with CTCAE term::Death NOS,0/22 %0.0,1/24 %4.17
Infection with normal ANC or Grade 1 or 2 neutrophils::Bladder (urinary),0/22 %0.0,1/24 %4.17
Infection with normal ANC or Grade 1 or 2 neutrophils::Lung (pneumonia),0/22 %0.0,1/24 %4.17
Hemoglobin,0/22 %0.0,2/24 %8.33
Pain::Back,0/22 %0.0,1/24 %4.17
Pain::Bone,0/22 %0.0,1/24 %4.17
Pain::Joint,0/22 %0.0,1/24 %4.17
Pain::Muscle,0/22 %0.0,1/24 %4.17
CNS cerebrovascular ischemia,0/22 %0.0,1/24 %4.17
Pain::Head/headache,0/22 %0.0,1/24 %4.17
Hypertension,1/22 %4.55,0/24 %0.0
Hypotension,1/22 %4.55,0/24 %0.0

BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00098254)
 ,BAY 43-9006 (Sorafenib)
 ,Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e. 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
Total serious adverse events,11/37 %29.73
Anemia,1/37 %2.7
Death NOS,1/37 %2.7
Fatigue,1/37 %2.7
Lung infection,2/37 %5.41
Alanine aminotransferase increased,1/37 %2.7
Alkaline phosphatase increased,1/37 %2.7
Aspartate aminotransferase increased,1/37 %2.7
Platelet count decreased,1/37 %2.7
Hypermagnesemia,1/37 %2.7
Hypoalbuminemia,1/37 %2.7
Hypomagnesemia,1/37 %2.7
Hyponatremia,1/37 %2.7
Confusion,1/37 %2.7
Bronchopulmonary hemorrhage,1/37 %2.7
Bronchospasm,1/37 %2.7
Cough,1/37 %2.7
Dyspnea,4/37 %10.81
Hypoxia,2/37 %5.41
Palmar-plantar erythrodysesthesia syndrome,1/37 %2.7
Hypertension,1/37 %2.7
Vasculitis,1/37 %2.7

Sorafenib in Treating Patients With Advanced or Metastatic Cancer of the Urinary Tract(https://clinicaltrials.gov/show/NCT00112671)
 ,Treatment (Sorafenib Tosylate)
 ,Patients receive oral sorafenib twice daily on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. sorafenib tosylate: Given orally laboratory biomarker analysis: Correlative studies
Total serious adverse events,2/17 %11.76
Multi-organ failure,1/17 %5.88
Death NOS,1/17 %5.88

Sorafenib in Treating Patients With Advanced Anaplastic Thyroid Cancer(https://clinicaltrials.gov/show/NCT00126568)
 ,BAY 43-9006
 ,BAY 43-9006 (sorafenib) will be administered on a fixed daily oral dosing schedule of 400 mg twice daily. A cycle of therapy will be considered 28 days (4 weeks / 1 month).
Total serious adverse events,8/20 %40.0
Edema: limb,1/20 %5.0
Lymphopenia,1/20 %5.0
Pain - Eye,1/20 %5.0
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/20 %5.0
Pain - Abdomen NOS(not otherwise specified),1/20 %5.0
Perforation GI - Appendix,1/20 %5.0
Death not associated with CTCAE term - Death NOS(not otherwise specified),1/20 %5.0
Death not associated with CTCAE term - Disease progression NOS(not otherwise specified),3/20 %15.0
Death not associated with CTCAE term - Sudden death,1/20 %5.0
Infection with unknown ANC(Absolute neutrophil count) - Lung (pneumonia),1/20 %5.0
Speech impairment (e.g. dysphasia or aphasia),1/20 %5.0
Dyspnea (shortness of breath),2/20 %10.0
Pneumothorax,1/20 %5.0
Pulmonary/Upper Respiratory,1/20 %5.0
Thrombosis/thrombus/embolism,1/20 %5.0

Sorafenib Tosylate With or Without Recombinant Interferon Alfa-2b in Treating Patients With Metastatic Kidney Cancer(https://clinicaltrials.gov/show/NCT00126594)
 ,Sorafenib Tosylate,Sorafenib Tosylate Recombinant Interferon Alfa-2b
 ,Arm I: Oral Sorafenib 400 mg twice daily on days 1-28.,Arm II: Sorafenib as in Arm I and low-dose Interferon alfa-2b 0.5 million units subcutaneously twice daily on days 1-28.
Total serious adverse events,29/40 %72.5,30/40 %75.0
Death,27/40 %67.5,29/40 %72.5
Pancreatitis,1/40 %2.5,0/40 %0.0
Appendicitis,1/40 %2.5,0/40 %0.0
Hyperuricemia,6/40 %15.0,2/40 %5.0
Serum amylase increased,1/40 %2.5,0/40 %0.0
Lipase Increased,0/40 %0.0,1/40 %2.5

Sorafenib Tosylate in Treating Patients With Progressive Metastatic Neuroendocrine Tumors(https://clinicaltrials.gov/show/NCT00131911)
 ,All Patients
 ,Patients receive 400 mg oral sorafenib twice daily on days 1-28.
Total serious adverse events,52/93 %55.91
Hemoglobin decreased,3/93 %3.23
Hypothyroidism,1/93 %1.08
Abdominal distension,1/93 %1.08
Abdominal pain,18/93 %19.35
Ascites,3/93 %3.23
Constipation,3/93 %3.23
Diarrhea,5/93 %5.38
Dry mouth,1/93 %1.08
Duodenal hemorrhage,1/93 %1.08
Duodenal perforation,1/93 %1.08
Duodenal ulcer,1/93 %1.08
Ear nose and throat examination abnormal,4/93 %4.3
Gastrointestinal disorder,2/93 %2.15
Intra-abdominal hemorrhage,1/93 %1.08
Lower gastrointestinal hemorrhage,1/93 %1.08
Mucositis oral,1/93 %1.08
Nausea,13/93 %13.98
Rectal fistula,1/93 %1.08
Small intestinal obstruction,3/93 %3.23
Small intestinal perforation,1/93 %1.08
Vomiting,8/93 %8.6
Chills,1/93 %1.08
Disease progression,1/93 %1.08
Edema limbs,3/93 %3.23
Fatigue,15/93 %16.13
Fever,4/93 %4.3
Localized edema,1/93 %1.08
Cholecystitis,1/93 %1.08
Gallbladder pain,1/93 %1.08
Hepatobiliary disease,1/93 %1.08
Hypersensitivity,1/93 %1.08
Bladder infection,1/93 %1.08
Pleural infection,1/93 %1.08
Pneumonia,1/93 %1.08
Sepsis,1/93 %1.08
Skin infection,1/93 %1.08
Alanine aminotransferase increased,1/93 %1.08
Alkaline phosphatase increased,3/93 %3.23
Aspartate aminotransferase increased,4/93 %4.3
Blood bilirubin increased,2/93 %2.15
Creatinine increased,1/93 %1.08
Leukocyte count decreased,1/93 %1.08
Lymphocyte count decreased,1/93 %1.08
Neutrophil count decreased,1/93 %1.08
Weight gain,1/93 %1.08
Weight loss,1/93 %1.08
Alkalosis,1/93 %1.08
Anorexia,10/93 %10.75
Blood glucose increased,2/93 %2.15
Dehydration,6/93 %6.45
Serum albumin decreased,3/93 %3.23
Serum calcium decreased,2/93 %2.15
Serum phosphate decreased,1/93 %1.08
Serum potassium decreased,3/93 %3.23
Serum potassium increased,3/93 %3.23
Serum sodium decreased,3/93 %3.23
Serum sodium increased,1/93 %1.08
Serum triglycerides increased,1/93 %1.08
Arthralgia,2/93 %2.15
Back pain,3/93 %3.23
Bone pain,1/93 %1.08
Myalgia,6/93 %6.45
Neck pain,1/93 %1.08
Pain in extremity,1/93 %1.08
Dizziness,2/93 %2.15
Headache,2/93 %2.15
Confusion,1/93 %1.08
Insomnia,1/93 %1.08
Dyspnea,6/93 %6.45
Pneumonitis,1/93 %1.08
Respiratory tract hemorrhage,1/93 %1.08
Voice alteration,2/93 %2.15
Alopecia,2/93 %2.15
Hand-and-foot syndrome,4/93 %4.3
Rash acneiform,4/93 %4.3
Rash desquamating,2/93 %2.15
Skin disorder,1/93 %1.08
Skin ulceration,1/93 %1.08
Sweating,3/93 %3.23
Flushing,1/93 %1.08
Hemorrhage,1/93 %1.08
Hot flashes,1/93 %1.08
Hypotension,2/93 %2.15
Thrombosis,2/93 %2.15

Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00182689)
 ,Platinum Sensitive,Platinum Refractory
 
Total serious adverse events,6/38 %15.79,7/44 %15.91
Diarrhea,0/38 %0.0,1/44 %2.27
Heartburn/dyspepsia,1/38 %2.63,0/44 %0.0
Nausea,1/38 %2.63,0/44 %0.0
Pain - Abdomen NOS,0/38 %0.0,1/44 %2.27
Pancreatitis,0/38 %0.0,1/44 %2.27
Fatigue (asthenia lethargy malaise),1/38 %2.63,0/44 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Urinary tract NOS,0/38 %0.0,1/44 %2.27
AST SGOT (serum glutamic oxaloacetic transaminase),1/38 %2.63,0/44 %0.0
Lipase,0/38 %0.0,1/44 %2.27
Dehydration,0/38 %0.0,1/44 %2.27
Sodium serum-low (hyponatremia),1/38 %2.63,2/44 %4.55
Muscle weakness generalized or specific area (not due to neuropathy) - Whole body/generalized,0/38 %0.0,1/44 %2.27
Pain - Joint,1/38 %2.63,0/44 %0.0
Ataxia (incoordination),0/38 %0.0,1/44 %2.27
Dizziness,1/38 %2.63,0/44 %0.0
Neuropathy: motor,1/38 %2.63,0/44 %0.0
Neuropathy: sensory,1/38 %2.63,0/44 %0.0
Pain - Head/headache,1/38 %2.63,0/44 %0.0
Speech impairment (e.g. dysphasia or aphasia),0/38 %0.0,1/44 %2.27
Syncope (fainting),1/38 %2.63,0/44 %0.0
Tremor,1/38 %2.63,0/44 %0.0
Confusion,1/38 %2.63,2/44 %4.55
Dyspnea (shortness of breath),1/38 %2.63,0/44 %0.0
Pleural effusion (non-malignant),0/38 %0.0,1/44 %2.27
Hypertension,1/38 %2.63,0/44 %0.0

Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00217399)
 ,Sorafenib and Anastrozole
 ,A single arm of 35 patients with advanced or metastatic breast cancer receiving a combination of sorafenib and anastrozole.
Total serious adverse events,12/35 %34.29
hand-foot syndome,12/35 %34.29

S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas(https://clinicaltrials.gov/show/NCT00217620)
 ,Sorafenib (BAY 43-9006)
 ,Sorafenib (BAY 43-9006) 800 mg per day divided into two equal doses of 400 mg by mouth (PO). Patients received the drug continuously on a daily basis until progression; each cycle is 28 days. All eligible patients who received treatment were included in baseline measures.
Total serious adverse events,10/37 %27.03
Hemoglobin,1/37 %2.7
Constipation,1/37 %2.7
Hemorrhage GI - Colon,1/37 %2.7
Nausea,1/37 %2.7
Pain - Abdomen NOS,3/37 %8.11
Pancreatitis,1/37 %2.7
Pain - Chest/thorax NOS,1/37 %2.7
AST SGOT,1/37 %2.7
Amylase,1/37 %2.7
Lipase,2/37 %5.41
Platelets,1/37 %2.7
Anorexia,1/37 %2.7
Calcium serum-low (hypocalcemia),1/37 %2.7
Potassium serum-low (hypokalemia),1/37 %2.7
Sodium serum-low (hyponatremia),1/37 %2.7
Death - Disease progression NOS,2/37 %5.41
Mental status,1/37 %2.7
Neuropathy: motor,1/37 %2.7
Syncope (fainting),1/37 %2.7
Obstruction GU - Ureter,1/37 %2.7
Dyspnea (shortness of breath),1/37 %2.7
Hypotension,1/37 %2.7

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery(https://clinicaltrials.gov/show/NCT00281957)
 ,Arm I,Arm II
 ,Sorafenib and Temsirolimu,Sorafenib and Tipifarnib
Total serious adverse events,13/63 %20.63,6/39 %15.38
Hemoglobin,1/63 %1.59,0/39 %0.0
Left ventricular systolic dysfunction,1/63 %1.59,0/39 %0.0
Ileus GI (functional obstruction of bowel i.e. neuroconstipation),1/63 %1.59,0/39 %0.0
Nausea,1/63 %1.59,0/39 %0.0
Pain - Abdomen NOS,1/63 %1.59,0/39 %0.0
Pancreatitis,1/63 %1.59,1/39 %2.56
Vomiting,2/63 %3.17,0/39 %0.0
Fatigue (asthenia lethargy malaise),1/63 %1.59,0/39 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Nose,1/63 %1.59,0/39 %0.0
Infection with normal ANC or Grade 1 or 2 neutrophils - Skin (cellulitis),1/63 %1.59,0/39 %0.0
Amylase,0/63 %0.0,1/39 %2.56
Lipase,0/63 %0.0,1/39 %2.56
Albumin serum-low (hypoalbuminemia),1/63 %1.59,0/39 %0.0
Calcium serum-low (hypocalcemia),1/63 %1.59,0/39 %0.0
Dehydration,2/63 %3.17,0/39 %0.0
Glucose serum-high (hyperglycemia),1/63 %1.59,0/39 %0.0
Phosphate serum-low (hypophosphatemia),2/63 %3.17,0/39 %0.0
Potassium serum-low (hypokalemia),2/63 %3.17,0/39 %0.0
Muscle weakness generalized or specific area (not due to neuropathy) - Whole body/generalized,2/63 %3.17,1/39 %2.56
Pain - Back,0/63 %0.0,1/39 %2.56
Pain - Joint,1/63 %1.59,0/39 %0.0
Neurology-Other (Specify),1/63 %1.59,0/39 %0.0
Neuropathy: motor,0/63 %0.0,1/39 %2.56
Pain - Head/headache,1/63 %1.59,0/39 %0.0
Confusion,1/63 %1.59,0/39 %0.0
Renal failure,1/63 %1.59,0/39 %0.0
Pneumonitis/pulmonary infiltrates,2/63 %3.17,0/39 %0.0
Pulmonary/Upper Respiratory-Other (Specify),1/63 %1.59,0/39 %0.0
Pruritus/itching,1/63 %1.59,0/39 %0.0
Rash/desquamation,1/63 %1.59,0/39 %0.0
Flushing,1/63 %1.59,0/39 %0.0
Hypertension,1/63 %1.59,1/39 %2.56
Thrombosis/thrombus/embolism,0/63 %0.0,1/39 %2.56

BAY 43-9006 Plus Cetuximab to Treat Colorectal Cancer(https://clinicaltrials.gov/show/NCT00326495)
 ,BAY 43-9006 & Cetuximab
 ,BAY 43-9006: Administered orally at a dose of 400 mg twice a day (BID) BAY 43-9006: is a potent inhibitor of proto-oncogene c-Raf (c-raf) and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro. Cetuximab will be given intravenously (IV) at a dose of 400 mg/m^2 initially as a loading dose on week 2 followed by 250 mg/m^2 weekly starting on week 3. Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR) human epidermal growth factor receptor 1 (HER1) c-ErbB) in normal and tumor cells and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands such as transforming growth factor-alpha.
Total all-cause mortality,2/50 %4.0
Total serious adverse events,22/50 %44.0
Anemia,2/50 %4.0
Abdominal distension,2/50 %4.0
Dehydration,1/50 %2.0
Diarrhea,1/50 %2.0
Duodenal obstruction,1/50 %2.0
Ileus,1/50 %2.0
Nausea,1/50 %2.0
Rectal hemorrhage,1/50 %2.0
Small intestinal obstruction,6/50 %12.0
Vomiting,2/50 %4.0
Chills,1/50 %2.0
Death NOS,2/50 %4.0
Fever,5/50 %10.0
Pain,1/50 %2.0
Anaphylaxis,1/50 %2.0
Bladder infection,2/50 %4.0
Catheter related infection,1/50 %2.0
Tooth infection,1/50 %2.0
Urinary tract infection,1/50 %2.0
Wound infection,1/50 %2.0
Blood bilirubin increased,1/50 %2.0
Lipase increased,1/50 %2.0
Hypokalemia,1/50 %2.0
Hyponatremia,1/50 %2.0
Back pain,1/50 %2.0
Headache,2/50 %4.0
Ischemia cerebrovascular,1/50 %2.0
Movements involuntary,1/50 %2.0
Hematuria,1/50 %2.0
Urinary tract obstruction,1/50 %2.0
Vaginal hemorrhage,1/50 %2.0

Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery(https://clinicaltrials.gov/show/NCT00326898)
 ,Arm A (Sunitinib + Sorafenib Placebo),Arm B (Sorafenib + Sunitinib Placebo),Arm C (Sunitinib Placebo + Sorafenib Placebo)
 ,Beginning 4-12 weeks following radical or partial nephrectomy patients receive sunitinib malate 37.5mg PO QD for 4 weeks and placebo sorafenib tosylate 400mg PO QD or BID for 6 weeks.,Beginning 4-12 weeks following radical or partial nephrectomy patients receive sorafenib tosylate 400mg PO QD or BID for 6 weeks and placebo sunitinib malate 37.5mg PO QD for 4 weeks followed.,Beginning 4-12 weeks following radical or partial nephrectomy patients receive placebo sorafenib tosylate 400mg as in Arm A and placebo sunitinib malate 37.5mg as in Arm B.
Total serious adverse events,368/625 %58.88,424/628 %67.52,81/626 %12.94
Anemia,2/625 %0.32,1/628 %0.16,0/626 %0.0
Thrombotic microangiopathy,1/625 %0.16,0/628 %0.0,0/626 %0.0
Febrile neutropenia,2/625 %0.32,0/628 %0.0,0/626 %0.0
Heart block abnormality NOS,0/625 %0.0,0/628 %0.0,1/626 %0.16
Atrial fibrillation,1/625 %0.16,0/628 %0.0,2/626 %0.32
Atrial flutter,0/625 %0.0,0/628 %0.0,2/626 %0.32
Sinus bradycardia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Supraventricular tachycardia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Bigeminy,1/625 %0.16,0/628 %0.0,0/626 %0.0
Cardiac-ischemia,1/625 %0.16,3/628 %0.48,4/626 %0.64
Left ventricular systolic dysfunction,4/625 %0.64,4/628 %0.64,2/626 %0.32
Cor Pulmonale,0/625 %0.0,1/628 %0.16,0/626 %0.0
cardiac-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Cardiac/heart pain,2/625 %0.32,3/628 %0.48,0/626 %0.0
Hearing w/o audiogr not in monitor prg,1/625 %0.16,0/628 %0.0,0/626 %0.0
Adrenal insufficiency,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hyopthyroidism,2/625 %0.32,0/628 %0.0,0/626 %0.0
Cataract,0/625 %0.0,0/628 %0.0,1/626 %0.16
Double vision,0/625 %0.0,0/628 %0.0,1/626 %0.16
Retinal detachment,1/625 %0.16,0/628 %0.0,0/626 %0.0
Ocular-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Colitis,0/625 %0.0,3/628 %0.48,0/626 %0.0
Constipation,1/625 %0.16,0/628 %0.0,0/626 %0.0
Diarrhea w/o prior colostomy,57/625 %9.12,55/628 %8.76,2/626 %0.32
Distention/bloating abdominal,0/625 %0.0,1/628 %0.16,0/626 %0.0
Esophagitis,0/625 %0.0,1/628 %0.16,0/626 %0.0
Gastritis,1/625 %0.16,1/628 %0.16,0/626 %0.0
Dyspepsia,14/625 %2.24,4/628 %0.64,1/626 %0.16
Ileus,0/625 %0.0,0/628 %0.0,1/626 %0.16
Muco/stomatitis by exam oral cavity,2/625 %0.32,0/628 %0.0,0/626 %0.0
Muco/stomatitis (symptom) oral cavity,3/625 %0.48,1/628 %0.16,0/626 %0.0
Nausea,22/625 %3.52,5/628 %0.8,0/626 %0.0
Perforation colon,0/625 %0.0,1/628 %0.16,0/626 %0.0
Vomiting,11/625 %1.76,3/628 %0.48,1/626 %0.16
Colon hemorrhage,2/625 %0.32,0/628 %0.0,0/626 %0.0
Lower GI hemorrhage NOS,0/625 %0.0,1/628 %0.16,0/626 %0.0
Stomach hemorrhage,1/625 %0.16,0/628 %0.0,0/626 %0.0
Pancreatitis,3/625 %0.48,1/628 %0.16,0/626 %0.0
Abdomen pain,4/625 %0.64,8/628 %1.27,2/626 %0.32
Esophagus pain,1/625 %0.16,0/628 %0.0,0/626 %0.0
Oral cavity pain,1/625 %0.16,1/628 %0.16,0/626 %0.0
Stomach pain,0/625 %0.0,1/628 %0.16,0/626 %0.0
Fatigue,108/625 %17.28,41/628 %6.53,15/626 %2.4
Fever w/o neutropenia,1/625 %0.16,2/628 %0.32,0/626 %0.0
Edema head and neck,3/625 %0.48,1/628 %0.16,0/626 %0.0
Edema limb,2/625 %0.32,0/628 %0.0,0/626 %0.0
Chest/thoracic pain NOS,4/625 %0.64,4/628 %0.64,0/626 %0.0
Pain-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Flu-like syndrome,3/625 %0.48,0/628 %0.0,0/626 %0.0
Cholecystitis,1/625 %0.16,0/628 %0.0,0/626 %0.0
Liver dysfunction/failure,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hepatic-other,1/625 %0.16,0/628 %0.0,0/626 %0.0
Allergic reaction,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection w/ gr3-4 neut ileum,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut appendix,0/625 %0.0,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut colon,0/625 %0.0,2/628 %0.32,0/626 %0.0
Infection Gr0-2 neut kidney,1/625 %0.16,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut lung,2/625 %0.32,3/628 %0.48,2/626 %0.32
Infection Gr0-2 neut mediastinm,0/625 %0.0,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut mucosa,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut muscle,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut nerve-cranial,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut skin,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut urinary tract,1/625 %0.16,0/628 %0.0,1/626 %0.16
Infection Gr0-2 neut vagina,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection Gr0-2 neut wound,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection w/ unk ANC skin (cellulitis),0/625 %0.0,2/628 %0.32,0/626 %0.0
Infection w/ unk ANC urinary tract NOS,0/625 %0.0,1/628 %0.16,0/626 %0.0
Infection Gr0-2 neut blood,1/625 %0.16,0/628 %0.0,0/626 %0.0
Infection-other,1/625 %0.16,1/628 %0.16,0/626 %0.0
Wound - non-infectious,0/625 %0.0,1/628 %0.16,0/626 %0.0
Vascular accessThrombosis/embolism,0/625 %0.0,1/628 %0.16,0/626 %0.0
Leukocytes decreased,3/625 %0.48,0/628 %0.0,0/626 %0.0
Neutrophils decreased,7/625 %1.12,2/628 %0.32,0/626 %0.0
Platelets decreased,13/625 %2.08,2/628 %0.32,1/626 %0.16
Weight gain,0/625 %0.0,0/628 %0.0,2/626 %0.32
Alanine aminotransferase increased,4/625 %0.64,4/628 %0.64,0/626 %0.0
Serum amylase increased,0/625 %0.0,1/628 %0.16,0/626 %0.0
Aspartate aminotransferase increased,6/625 %0.96,4/628 %0.64,0/626 %0.0
Blood bilirubin increased,1/625 %0.16,1/628 %0.16,1/626 %0.16
Hypercholesterolemia,1/625 %0.16,0/628 %0.0,0/626 %0.0
CPK increased,1/625 %0.16,1/628 %0.16,0/626 %0.0
Creatinine increased,1/625 %0.16,3/628 %0.48,0/626 %0.0
Lipase increased,4/625 %0.64,3/628 %0.48,1/626 %0.16
Anorexia,11/625 %1.76,5/628 %0.8,0/626 %0.0
Dehydration,10/625 %1.6,3/628 %0.48,0/626 %0.0
Hypoalbuminemia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hypocalcemia,1/625 %0.16,1/628 %0.16,0/626 %0.0
Hyperglycemia,0/625 %0.0,1/628 %0.16,1/626 %0.16
Hypophosphatemia,1/625 %0.16,1/628 %0.16,0/626 %0.0
Hyperkalemia,3/625 %0.48,1/628 %0.16,0/626 %0.0
Hypokalemia,2/625 %0.32,1/628 %0.16,0/626 %0.0
Hypernatremia,1/625 %0.16,0/628 %0.0,0/626 %0.0
Hyponatremia,1/625 %0.16,5/628 %0.8,4/626 %0.64
Hypertriglyceridemia,2/625 %0.32,0/628 %0.0,0/626 %0.0
Hyperuricemia,0/625 %0.0,1/628 %0.16,3/626 %0.48
Nonneuropathic upper extr muscle weak,1/625 %0.16,0/628 %0.0,0/626 %0.0
Nonneuropathic left-side muscle weak,0/625 %0.0,1/628 %0.16,0/626 %0.0
Nonneuropathic right-side muscle weak,0/625 %0.0,0/628 %0.0,1/626 %0.16
Nonneuropathic generalized weakness,1/625 %0.16,1/628 %0.16,1/626 %0.16
Myositis,1/625 %0.16,0/628 %0.0,0/626 %0.0
Musculoskeletal/soft tissue-other,0/625 %0.0,2/628 %0.32,0/626 %0.0
Back pain,1/625 %0.16,3/628 %0.48,0/626 %0.0
Bone pain,2/625 %0.32,1/628 %0.16,0/626 %0.0
Extremity-limb pain,4/625 %0.64,3/628 %0.48,0/626 %0.0
Joint pain,8/625 %1.28,8/628 %1.27,3/626 %0.48
Muscle pain,2/625 %0.32,8/628 %1.27,1/626 %0.16
Secondary malignancy,0/625 %0.0,1/628 %0.16,1/626 %0.16
Vasovagal episode,1/625 %0.16,0/628 %0.0,0/626 %0.0
Ataxia,0/625 %0.0,0/628 %0.0,1/626 %0.16
CNS cerebrovascular ischemia,4/625 %0.64,0/628 %0.0,1/626 %0.16
Cognitive disturbance,0/625 %0.0,1/628 %0.16,0/626 %0.0
Dizziness,4/625 %0.64,2/628 %0.32,2/626 %0.32
Memory impairment,1/625 %0.16,0/628 %0.0,1/626 %0.16
Neuropathy-motor,3/625 %0.48,1/628 %0.16,0/626 %0.0
Neuropathy-sensory,3/625 %0.48,12/628 %1.91,3/626 %0.48
Syncope,4/625 %0.64,2/628 %0.32,0/626 %0.0
Head/headache,6/625 %0.96,4/628 %0.64,0/626 %0.0
Insomnia,0/625 %0.0,4/628 %0.64,0/626 %0.0
Confusion,2/625 %0.32,0/628 %0.0,1/626 %0.16
Anxiety,0/625 %0.0,1/628 %0.16,0/626 %0.0
Depression,1/625 %0.16,2/628 %0.32,2/626 %0.32
Kidney hemorrhage,1/625 %0.16,0/628 %0.0,0/626 %0.0
Proteinuria,2/625 %0.32,2/628 %0.32,0/626 %0.0
Renal failure,6/625 %0.96,4/628 %0.64,0/626 %0.0
Renal/GU-other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Sexual/Reproductive function-Other,0/625 %0.0,1/628 %0.16,0/626 %0.0
Pulmonary hypertension,0/625 %0.0,0/628 %0.0,1/626 %0.16
Muco/stomatitis (symptom) pharynx,24/625 %3.84,14/628 %2.23,0/626 %0.0
Nose hemorrhage,3/625 %0.48,0/628 %0.0,0/626 %0.0
Dyspnea,4/625 %0.64,4/628 %0.64,2/626 %0.32
Pleural effusion (non-malignant),1/625 %0.16,1/628 %0.16,0/626 %0.0
Voice changes/dysarthria,0/625 %0.0,1/628 %0.16,0/626 %0.0
Dry skin,0/625 %0.0,1/628 %0.16,0/626 %0.0
Nail changes,1/625 %0.16,0/628 %0.0,0/626 %0.0
Pruritus/itching,1/625 %0.16,11/628 %1.75,1/626 %0.16
Rash/desquamation,15/625 %2.4,93/628 %14.81,3/626 %0.48
Rash: acne/acneiform,0/625 %0.0,2/628 %0.32,0/626 %0.0
Erythema multiforme,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hand-foot reaction,94/625 %15.04,208/628 %33.12,7/626 %1.12
Urticaria,0/625 %0.0,1/628 %0.16,0/626 %0.0
Scalp pain,0/625 %0.0,2/628 %0.32,0/626 %0.0
Skin pain,0/625 %0.0,1/628 %0.16,0/626 %0.0
Hypertension,104/625 %16.64,96/628 %15.29,15/626 %2.4
Hypotension,1/625 %0.16,0/628 %0.0,0/626 %0.0
Thrombosis/thrombus/embolism,3/625 %0.48,5/628 %0.8,1/626 %0.16
Vascular-Other (Specify),0/625 %0.0,1/628 %0.16,0/626 %0.0

Sorafenib  Carboplatin  and Paclitaxel in Treating Patients With Stage IV Melanoma of the Eye(https://clinicaltrials.gov/show/NCT00329641)
 ,Intervention
 ,Sorafenib Carboplatin Paclitaxel
Total serious adverse events,2/24 %8.33
Neutrophils/granulocytes (ANC/AGC),1/24 %4.17
Rash/desquamation,1/24 %4.17

Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07)(https://clinicaltrials.gov/show/NCT00330421)
 ,Group II (Metastatic or Inoperable Sarcomas)
 ,Patients receive oral sorafenib twice daily on days 1-28. Treatment repeats every 28 days for 2 courses. Patients with responding or stable disease may continue sorafenib in the absence of disease progression or unacceptable toxicity. Biopsy tissue and blood samples are examined for biomarkers and IFP is measured at baseline and on days 28 and 56. laboratory biomarker analysis : Correlative studies sorafenib tosylate : Given PO pharmacological study : Correlative studies computed tomography : Correlative studies dynamic contrast-enhanced magnetic resonance imaging : Correlative studies
Total serious adverse events,11/15 %73.33
Hemoglobin,8/15 %53.33
Hematologic - other,6/15 %40.0
Diarrhea,6/15 %40.0
Abdominal pain,5/15 %33.33
Fatigue,11/15 %73.33
Anorexia,5/15 %33.33
Alkaline phosphatase,7/15 %46.67
AST,7/15 %46.67

Sorafenib Combined With Erlotinib  Tipifarnib  or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma(https://clinicaltrials.gov/show/NCT00335764)
 ,Group 1 Phase I Sorafenib and Erlotinib,Group 2 Phase I Sorafenib and Temsirolimus,Group 3 Phase I Sorafenib and Tipifarnib,Group 1 Phase II Sorafenib and Erlotinib,Group 2 Phase II Sorafenib and Temsirolimus
 ,Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28. sorafenib tosylate: given orally erlotinib hydrochloride: given orally,Patients receive sorafenib tosylate as in group 2. Patients also receive temsirolimus IV over 30 minutes on days 1 8 15 and 22. sorafenib tosylate: given orally temsirolimus: IV administration,Patients receive sorafenib tosylate as in group 3. Patients also receive oral tipifarnib twice daily on days 1-21. sorafenib tosylate: given orally tipifarnib: given orally,Patients receive oral sorafenib tosylate twice daily and oral erlotinib hydrochloride once daily on days 1-28. sorafenib tosylate: given orally erlotinib hydrochloride: given orally,Patients receive sorafenib tosylate 400 mg BID as in group 2. Patients also receive temsirolimus IV 25 mg over 30 minutes on days 1 8 15 and 22. sorafenib tosylate: given orally temsirolimus: IV administration
Total all-cause mortality,15/16 %93.75,13/13 %100.0,24/24 %100.0,19/19 %100.0,18/18 %100.0
Total serious adverse events,0/16 %0.0,0/13 %0.0,4/24 %16.67,1/19 %5.26,2/18 %11.11
Abdominal pain,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Diarrhea,0/16 %0.0,0/13 %0.0,0/24 %0.0,1/19 %5.26,1/18 %5.56
Pancrease infection,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Lipase increased,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Serum amylase increased,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Hypertriglyceridemia,0/16 %0.0,0/13 %0.0,0/24 %0.0,0/19 %0.0,1/18 %5.56
Encephalopathy,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Headache,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Seizure,0/16 %0.0,0/13 %0.0,0/24 %0.0,0/19 %0.0,1/18 %5.56
Confusion,0/16 %0.0,0/13 %0.0,1/24 %4.17,1/19 %5.26,0/18 %0.0
Rash acneiform,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Hypertension,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0
Thromboembolic event,0/16 %0.0,0/13 %0.0,1/24 %4.17,0/19 %0.0,0/18 %0.0

Sorafenib Tosylate in Treating Patients With Metastatic  Locally Advanced  or Recurrent Medullary Thyroid Cancer(https://clinicaltrials.gov/show/NCT00390325)
 ,Arm A (Hereditary MTC) and Arm B (Sporadic MTC)
 ,Arm A: Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis. Arm B: Sorafenib (BAY 43-9006) was administered at the dose of 400 mg orally twice a day on a continuous basis.
Total all-cause mortality,1/21 %4.76
Total serious adverse events,5/21 %23.81
Cardiac ischemia/infarction,1/21 %4.76
Perforation GI-small bowel,1/21 %4.76
Infection,1/21 %4.76
Hypokalemia,1/21 %4.76
Renal Failure,1/21 %4.76
Thrombosis/Thrombus/embois,1/21 %4.76

Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer(https://clinicaltrials.gov/show/NCT00390611)
 ,Paclitaxel/Carboplatin/Sorafenib,Paclitaxel/Carboplatin
 ,Paclitaxel 175 mg/m2 1-3 hour IV infusion Day 1 Carboplatin AUC 6 infused over 20 minutes IV Day 1 Sorafenib 400mg PO bid Sorafenib Paclitaxel: Paclitaxel Carboplatin: Carboplatin,Paclitaxel 175 mg/m2 1-3 hour IV infusion Day 1 Carboplatin AUC 6 infused over 20 minutes IV Paclitaxel: Paclitaxel Carboplatin: Carboplatin
Total serious adverse events,12/43 %27.91,10/42 %23.81
Anemia,0/43 %0.0,1/42 %2.38
Febrile neutropenia,1/43 %2.33,0/42 %0.0
Atrial fibrillation,1/43 %2.33,0/42 %0.0
Abdominal pain,3/43 %6.98,2/42 %4.76
Nausea,1/43 %2.33,3/42 %7.14
Vomiting,1/43 %2.33,3/42 %7.14
Gastrointestinal disorders - Other small bowel obstruction,1/43 %2.33,1/42 %2.38
Colitis,0/43 %0.0,1/42 %2.38
Constipation,0/43 %0.0,1/42 %2.38
Diarrhea,0/43 %0.0,1/42 %2.38
Gastrointestinal disorders - Other hemorrhage,0/43 %0.0,1/42 %2.38
Lower gastrointestinal hemorrhage,1/43 %2.33,0/42 %0.0
Upper gastrointestinal hemorrhage,1/43 %2.33,0/42 %0.0
General disorders and administration site conditions - Other disease progression,1/43 %2.33,0/42 %0.0
General disorders and administration site conditions - Other failure to thrive,0/43 %0.0,1/42 %2.38
Infusion related reaction,1/43 %2.33,0/42 %0.0
Cholecystitis,1/43 %2.33,0/42 %0.0
Allergic reaction,4/43 %9.3,1/42 %2.38
Investigations - Other pancytopenia,0/43 %0.0,1/42 %2.38
Dehydration,0/43 %0.0,3/42 %7.14
Hypokalemia,0/43 %0.0,1/42 %2.38
Metabolism and nutrition disorders - Other electrolyte imbalance,0/43 %0.0,1/42 %2.38
Dyspnea,1/43 %2.33,0/42 %0.0
Pleural effusion,1/43 %2.33,0/42 %0.0
Rash,1/43 %2.33,0/42 %0.0
Thromboembolic event,1/43 %2.33,1/42 %2.38
Hypotension,0/43 %0.0,1/42 %2.38

Sorafenib and Bevacizumab to Treat Ovarian  Fallopian and Peritoneal Cancer(https://clinicaltrials.gov/show/NCT00436215)
 ,BAY 43-9006 + Bevacizumab
 ,BAY 43-9006 (sorafenib) + Bevacizumab Bevacizumab: bevacizumab 5 mg/kg intravenous (IV) every two weeks BAY 43-9006: BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
Total all-cause mortality,1/55 %1.82
Total serious adverse events,25/55 %45.45
Pericardial effusion,1/55 %1.82
Abdominal pain,5/55 %9.09
Diarrhea,1/55 %1.82
Gastrointestinal disorders - Other specify,1/55 %1.82
Nausea,2/55 %3.64
Obstruction gastric,1/55 %1.82
Small intestinal obstruction,7/55 %12.73
Vomiting,1/55 %1.82
Fever,2/55 %3.64
Hepatobiliary disorders - Other specify (bile duct obstruction),1/55 %1.82
Allergic reaction,1/55 %1.82
Catheter related infection,1/55 %1.82
Cecal infection,1/55 %1.82
Wound infection,1/55 %1.82
Vascular access complication,1/55 %1.82
Dehydration,1/55 %1.82
Hyponatremia,1/55 %1.82
Headache,1/55 %1.82
Urinary tract obstruction,1/55 %1.82
Pleural effusion,2/55 %3.64
Pneumonitis,1/55 %1.82
Hypertension,1/55 %1.82
Thromboembolic event,4/55 %7.27
Vascular disorders - Other specify,1/55 %1.82

Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00454194)
 ,Arm I (Pemetrexed + Sorafenib),Arm II (Pemetrexed)
 ,Patients receive oral sorafenib tosylate twice daily on days 1-21 and pemetrexed disodium IV over 10 minutes on day 1.,Patients receive pemetrexed disodium IV over 10 minutes on day 1.
Total serious adverse events,13/47 %27.66,7/51 %13.73
Febrile neutropenia,1/47 %2.13,0/51 %0.0
Hemoglobin decreased,1/47 %2.13,2/51 %3.92
Abdominal pain,2/47 %4.26,0/51 %0.0
Dry mouth,1/47 %2.13,0/51 %0.0
Small intestinal perforation,1/47 %2.13,0/51 %0.0
Vomiting,0/47 %0.0,1/51 %1.96
Fatigue,1/47 %2.13,0/51 %0.0
Sudden death,1/47 %2.13,0/51 %0.0
Aspartate aminotransferase increased,1/47 %2.13,0/51 %0.0
Bilirubin increased,0/47 %0.0,1/51 %1.96
Leukocyte count decreased,1/47 %2.13,1/51 %1.96
Lipase increased,0/47 %0.0,1/51 %1.96
Neutrophil count decreased,4/47 %8.51,1/51 %1.96
Platelet count decreased,3/47 %6.38,2/51 %3.92
Weight loss,1/47 %2.13,0/51 %0.0
Anorexia,1/47 %2.13,0/51 %0.0
Chest wall pain,0/47 %0.0,1/51 %1.96
Headache,0/47 %0.0,1/51 %1.96
Ischemia cerebrovascular,1/47 %2.13,0/51 %0.0
Bronchial hemorrhage,1/47 %2.13,1/51 %1.96
Dyspnea,0/47 %0.0,2/51 %3.92
Thrombosis,0/47 %0.0,1/51 %1.96

Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib(https://clinicaltrials.gov/show/NCT00474786)
 ,Temsirolimus,Sorafenib
 ,Temsirolimus 25 milligrams (mg) once weekly by intravenous (IV) infusion administered in 6 week cycles for up to 24 months participants were premedicated with 25-50 mg IV diphenydramine 30 minutes before temsirolimus infusion. In event of toxicity dose could be modified or held according to the protocol or at the discretion of the investigator.,Sorafenib 400 mg (two 200 mg tablets) by mouth (PO) twice daily (BID) administered in 6 week cycles for up to 24 months. In event of toxicity dose could be modified or held according to the protocol or at the discretion of the investigator.
Total serious adverse events,104/249 %41.77,87/252 %34.52
Anaemia,5/249 %2.01,4/252 %1.59
Febrile neutropenia,1/249 %0.4,0/252 %0.0
Lymphopenia,1/249 %0.4,0/252 %0.0
Thrombocytopenia,1/249 %0.4,0/252 %0.0
Acute myocardial infarction,1/249 %0.4,0/252 %0.0
Atrial fibrillation,0/249 %0.0,3/252 %1.19
Atrial flutter,0/249 %0.0,1/252 %0.4
Cardiac arrest,1/249 %0.4,0/252 %0.0
Cardiac tamponade,1/249 %0.4,0/252 %0.0
Cardio-respiratory arrest,1/249 %0.4,1/252 %0.4
Cardiopulmonary failure,2/249 %0.8,0/252 %0.0
Myocardial infarction,1/249 %0.4,4/252 %1.59
Myocardial ischaemia,0/249 %0.0,1/252 %0.4
Palpitations,0/249 %0.0,1/252 %0.4
Pericardial effusion,1/249 %0.4,0/252 %0.0
Prinzmetal angina,1/249 %0.4,0/252 %0.0
Hyperthyroidism,0/249 %0.0,1/252 %0.4
Toxic nodular goitre,0/249 %0.0,1/252 %0.4
Retinal artery occlusion,0/249 %0.0,1/252 %0.4
Abdominal distension,1/249 %0.4,1/252 %0.4
Abdominal pain,7/249 %2.81,1/252 %0.4
Ascites,3/249 %1.2,1/252 %0.4
Constipation,1/249 %0.4,1/252 %0.4
Diarrhoea,3/249 %1.2,1/252 %0.4
Duodenal perforation,1/249 %0.4,0/252 %0.0
Dysphagia,0/249 %0.0,1/252 %0.4
Gastrointestinal haemorrhage,0/249 %0.0,1/252 %0.4
Gastrointestinal obstruction,2/249 %0.8,0/252 %0.0
Hernial eventration,1/249 %0.4,0/252 %0.0
Hiatus hernia,0/249 %0.0,1/252 %0.4
Intestinal obstruction,1/249 %0.4,0/252 %0.0
Intestinal ulcer perforation,1/249 %0.4,0/252 %0.0
Large intestine perforation,0/249 %0.0,1/252 %0.4
Nausea,1/249 %0.4,0/252 %0.0
Obstruction gastric,0/249 %0.0,1/252 %0.4
Oesophageal hypomotility,1/249 %0.4,0/252 %0.0
Rectal haemorrhage,1/249 %0.4,0/252 %0.0
Salivary hypersecretion,1/249 %0.4,0/252 %0.0
Stomatitis,1/249 %0.4,0/252 %0.0
Vomiting,6/249 %2.41,4/252 %1.59
Asthenia,3/249 %1.2,1/252 %0.4
Chest pain,1/249 %0.4,3/252 %1.19
Fatigue,2/249 %0.8,4/252 %1.59
General physical health deterioration,8/249 %3.21,9/252 %3.57
Multi-organ failure,0/249 %0.0,1/252 %0.4
Oedema peripheral,2/249 %0.8,0/252 %0.0
Pain,1/249 %0.4,2/252 %0.79
Performance status decreased,1/249 %0.4,0/252 %0.0
Pyrexia,7/249 %2.81,4/252 %1.59
Sudden death,1/249 %0.4,1/252 %0.4
Systemic inflammatory response syndrome,0/249 %0.0,1/252 %0.4
Cholecystitis acute,1/249 %0.4,0/252 %0.0
Bile duct stone,1/249 %0.4,0/252 %0.0
Cholecystitis,1/249 %0.4,0/252 %0.0
Cholestasis,1/249 %0.4,0/252 %0.0
Gallbladder obstruction,0/249 %0.0,1/252 %0.4
Hepatobiliary disease,0/249 %0.0,1/252 %0.4
Anaphylactic reaction,1/249 %0.4,0/252 %0.0
Drug hypersensitivity,0/249 %0.0,1/252 %0.4
Abdominal infection,1/249 %0.4,0/252 %0.0
Abscess intestinal,0/249 %0.0,1/252 %0.4
Anal abscess,0/249 %0.0,1/252 %0.4
Bronchitis,1/249 %0.4,0/252 %0.0
Chest wall abscess,0/249 %0.0,1/252 %0.4
Cholangitis suppurative,0/249 %0.0,1/252 %0.4
Device related infection,2/249 %0.8,0/252 %0.0
Enterococcal bacteraemia,0/249 %0.0,1/252 %0.4
Hepatitis B,1/249 %0.4,0/252 %0.0
Herpes zoster,1/249 %0.4,0/252 %0.0
Infection,0/249 %0.0,1/252 %0.4
Infectious pleural effusion,0/249 %0.0,1/252 %0.4
Lobar pneumonia,1/249 %0.4,0/252 %0.0
Lower respiratory tract infection,2/249 %0.8,0/252 %0.0
Lung infection,1/249 %0.4,0/252 %0.0
Perirectal abscess,1/249 %0.4,0/252 %0.0
Pharyngitis,1/249 %0.4,0/252 %0.0
Pneumocystis jiroveci pneumonia,1/249 %0.4,0/252 %0.0
Pneumonia,7/249 %2.81,7/252 %2.78
Pneumonia influenzal,1/249 %0.4,0/252 %0.0
Pneumonia legionella,1/249 %0.4,0/252 %0.0
Pulmonary tuberculosis,0/249 %0.0,1/252 %0.4
Respiratory tract infection,1/249 %0.4,0/252 %0.0
Sepsis,2/249 %0.8,2/252 %0.79
Septic shock,1/249 %0.4,0/252 %0.0
Subcutaneous abscess,1/249 %0.4,0/252 %0.0
Tooth abscess,0/249 %0.0,1/252 %0.4
Urosepsis,0/249 %0.0,1/252 %0.4
Wound infection,0/249 %0.0,1/252 %0.4
Compression fracture,1/249 %0.4,0/252 %0.0
Hip fracture,0/249 %0.0,1/252 %0.4
Humerus fracture,0/249 %0.0,1/252 %0.4
Infusion related reaction,1/249 %0.4,0/252 %0.0
Ligament sprain,0/249 %0.0,1/252 %0.4
Lumbar vertebral fracture,1/249 %0.4,0/252 %0.0
Overdose,0/249 %0.0,1/252 %0.4
Pelvic fracture,1/249 %0.4,0/252 %0.0
Radiation mucositis,0/249 %0.0,1/252 %0.4
Alanine aminotransferase increased,0/249 %0.0,2/252 %0.79
Aspartate aminotransferase increased,0/249 %0.0,3/252 %1.19
Blood potassium increased,0/249 %0.0,1/252 %0.4
Prostatic specific antigen increased,0/249 %0.0,1/252 %0.4
Weight decreased,0/249 %0.0,1/252 %0.4
Cachexia,1/249 %0.4,0/252 %0.0
Decreased appetite,0/249 %0.0,2/252 %0.79
Dehydration,7/249 %2.81,6/252 %2.38
Diabetes mellitus inadequate control,1/249 %0.4,0/252 %0.0
Hypercalcaemia,1/249 %0.4,3/252 %1.19
Hypercholesterolaemia,1/249 %0.4,0/252 %0.0
Hyperglycaemia,2/249 %0.8,1/252 %0.4
Hyperkalaemia,0/249 %0.0,1/252 %0.4
Hypertriglyceridaemia,1/249 %0.4,0/252 %0.0
Hyponatraemia,0/249 %0.0,3/252 %1.19
Malnutrition,0/249 %0.0,1/252 %0.4
Arthralgia,2/249 %0.8,0/252 %0.0
Back pain,0/249 %0.0,3/252 %1.19
Bone lesion,1/249 %0.4,0/252 %0.0
Bone pain,1/249 %0.4,0/252 %0.0
Costochondritis,0/249 %0.0,1/252 %0.4
Flank pain,1/249 %0.4,0/252 %0.0
Intervertebral disc protrusion,0/249 %0.0,1/252 %0.4
Musculoskeletal chest pain,0/249 %0.0,1/252 %0.4
Musculoskeletal pain,1/249 %0.4,0/252 %0.0
Neck pain,0/249 %0.0,1/252 %0.4
Osteolysis,1/249 %0.4,1/252 %0.4
Pain in extremity,2/249 %0.8,3/252 %1.19
Pathological fracture,1/249 %0.4,0/252 %0.0
Spinal disorder,0/249 %0.0,1/252 %0.4
Malignant pleural effusion,1/249 %0.4,0/252 %0.0
Squamous cell carcinoma,0/249 %0.0,2/252 %0.79
Cerebral infarction,0/249 %0.0,1/252 %0.4
Cerebral ischaemia,0/249 %0.0,1/252 %0.4
Cerebrovascular accident,2/249 %0.8,0/252 %0.0
Cognitive disorder,0/249 %0.0,1/252 %0.4
Convulsion,0/249 %0.0,1/252 %0.4
Headache,1/249 %0.4,1/252 %0.4
Hypoaesthesia,0/249 %0.0,1/252 %0.4
Paraesthesia,1/249 %0.4,0/252 %0.0
Peripheral motor neuropathy,0/249 %0.0,1/252 %0.4
Spinal cord compression,1/249 %0.4,2/252 %0.79
Syncope,0/249 %0.0,1/252 %0.4
Unresponsive to stimuli,0/249 %0.0,1/252 %0.4
Completed suicide,1/249 %0.4,1/252 %0.4
Confusional state,0/249 %0.0,3/252 %1.19
Haematuria,1/249 %0.4,0/252 %0.0
Nephrotic syndrome,0/249 %0.0,1/252 %0.4
Renal failure,4/249 %1.61,1/252 %0.4
Renal failure acute,1/249 %0.4,1/252 %0.4
Renal tubular necrosis,1/249 %0.4,0/252 %0.0
Urinary retention,2/249 %0.8,0/252 %0.0
Prostatic haemorrhage,0/249 %0.0,1/252 %0.4
Asthmatic crisis,0/249 %0.0,1/252 %0.4
Dyspnoea,7/249 %2.81,8/252 %3.17
Epistaxis,1/249 %0.4,0/252 %0.0
Haemoptysis,0/249 %0.0,1/252 %0.4
Interstitial lung disease,2/249 %0.8,0/252 %0.0
Lung disorder,2/249 %0.8,0/252 %0.0
Pleural effusion,7/249 %2.81,5/252 %1.98
Pleuritic pain,1/249 %0.4,0/252 %0.0
Pneumonitis,7/249 %2.81,0/252 %0.0
Pneumothorax,3/249 %1.2,0/252 %0.0
Pulmonary embolism,1/249 %0.4,0/252 %0.0
Respiratory arrest,0/249 %0.0,1/252 %0.4
Respiratory distress,1/249 %0.4,0/252 %0.0
Respiratory failure,2/249 %0.8,2/252 %0.79
Palmar-plantar erythrodysaesthesia syndrome,0/249 %0.0,1/252 %0.4
Rash,1/249 %0.4,2/252 %0.79
Rash papular,0/249 %0.0,1/252 %0.4
Lung operation,1/249 %0.4,0/252 %0.0
Medical device implantation,1/249 %0.4,0/252 %0.0
Haematoma,0/249 %0.0,1/252 %0.4
Haemorrhage,1/249 %0.4,0/252 %0.0
Hypertension,1/249 %0.4,0/252 %0.0
Hypotension,1/249 %0.4,0/252 %0.0
Thrombosis,1/249 %0.4,0/252 %0.0

Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma(https://clinicaltrials.gov/show/NCT00474929)
 ,Phase I Dose Level 0,Phase I Dose Level 1,Phase I Dose Level 2,Phase I Dose Level 3,Phase II
 ,Phase I: Dose level 0: Sorafenib 200 mg twice daily RAD001 5mg every other day,Phase I: Dose level 1: Sorafenib 200 mg twice daily RAD001 5mg every day,Phase I: Dose level 2: Sorafenib 400 mg twice daily RAD001 5mg every day,Phase I: Dose level 3: Sorafenib 400 mg twice daily RAD001 10mg every day,Phase II: Sorafenib 200 mg twice daily RAD001 5mg every day;
Total serious adverse events,2/6 %33.33,1/5 %20.0,2/5 %40.0,1/5 %20.0,22/77 %28.57
Hemoglobin decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,3/77 %3.9
Cardiac valve disease,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sinus bradycardia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Diarrhea,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Ear nose and throat examination abnormal,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Nausea,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Death,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Disease progression,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Fatigue,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Fever,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sudden death,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hypersensitivity,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Infectious colitis,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Sepsis,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Bilirubin increased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Leukocyte count decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,2/77 %2.6
Lymphocyte count decreased,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Neutrophil count decreased,1/6 %16.67,0/5 %0.0,1/5 %20.0,0/5 %0.0,2/77 %2.6
Platelet count decreased,1/6 %16.67,1/5 %20.0,1/5 %20.0,1/5 %20.0,2/77 %2.6
Anorexia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Myalgia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Tumor pain,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,0/77 %0.0
Ataxia,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hand-and-foot syndrome,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Rash desquamating,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,2/77 %2.6
Urticaria,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Hypotension,0/6 %0.0,0/5 %0.0,0/5 %0.0,0/5 %0.0,1/77 %1.3
Thrombosis,0/6 %0.0,0/5 %0.0,1/5 %20.0,0/5 %0.0,0/77 %0.0

Capecitabine and Cisplatin (XP)+Sorafenib in Advanced Gastric Cancer (AGC): Sorafenib+XP(https://clinicaltrials.gov/show/NCT00565370)
 ,XP Plus Sorafenib
 ,Capecitabine and cisplatin plus sorafenib
Total serious adverse events,4/21 %19.05
Febrile neutropenia,1/21 %4.76
Deep vein thrombosis,2/21 %9.52
Diarrhea,1/21 %4.76
Gastric perforation,1/21 %4.76

Sorafenib and Letrozole  Anastrozole  or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00573755)
 ,Sorafenib Plus Aromatase Inhibitor,Placebo Plus Aromatase Inhibitor
 ,Patients receive oral sorafenib tosylate twice daily and oral letrozole anastrozole or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.,Patients receive oral placebo twice daily and oral letrozole anastrozole or exemestane once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,1/2 %50.0,0/2 %0.0
Hemoglobin decreased,1/2 %50.0,0/2 %0.0
Thrombotic microangiopathy,1/2 %50.0,0/2 %0.0
Ear nose and throat examination abnormal,1/2 %50.0,0/2 %0.0
Mucositis oral,1/2 %50.0,0/2 %0.0
Fatigue,1/2 %50.0,0/2 %0.0
Platelet count decreased,1/2 %50.0,0/2 %0.0
Serum potassium increased,1/2 %50.0,0/2 %0.0
Serum sodium decreased,1/2 %50.0,0/2 %0.0
Muscle weakness,1/2 %50.0,0/2 %0.0

Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib(https://clinicaltrials.gov/show/NCT00609804)
 ,Sorafenib+Erlotinib,Sorafenib
 ,Sorafenib and Erlotinib: Sorafenib 400 mg twice daily by mouth Erlotinib 150 mg once daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.,Sorafenib: Sorafenib 400 mg twice daily by mouth. Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
Total serious adverse events,11/25 %44.0,5/28 %17.86
Cardiac disorders - Other unspecified,1/25 %4.0,0/28 %0.0
Heart Failure,1/25 %4.0,0/28 %0.0
Constipation,1/25 %4.0,1/28 %3.57
Diarrhea,3/25 %12.0,0/28 %0.0
Dysphagia,1/25 %4.0,0/28 %0.0
Gastric perforation,1/25 %4.0,0/28 %0.0
Ileus,1/25 %4.0,0/28 %0.0
Nausea,1/25 %4.0,0/28 %0.0
Obstruction gastric,1/25 %4.0,0/28 %0.0
Abdominal pain,1/25 %4.0,0/28 %0.0
Vomiting,1/25 %4.0,0/28 %0.0
Fatigue,2/25 %8.0,0/28 %0.0
Non-cardiac chest pain,0/25 %0.0,1/28 %3.57
Anorexia,1/25 %4.0,0/28 %0.0
Dehydration,3/25 %12.0,0/28 %0.0
Hyperglycemia,1/25 %4.0,0/28 %0.0
Hypokalemia,0/25 %0.0,1/28 %3.57
Hyponatremia,1/25 %4.0,0/28 %0.0
Dizziness,0/25 %0.0,1/28 %3.57
Intracranial hemorrhage,1/25 %4.0,0/28 %0.0
Peripheral motor neuropathy,1/25 %4.0,0/28 %0.0
Cognitive disturbance,1/25 %4.0,0/28 %0.0
Confusion,0/25 %0.0,1/28 %3.57
Personality change,1/25 %4.0,0/28 %0.0
Respiratory thoracic and mediastinal disorders - Other COPD exacerbation,0/25 %0.0,1/28 %3.57
Cough,1/25 %4.0,0/28 %0.0
Respiratory failure,1/25 %4.0,0/28 %0.0
Rash,0/25 %0.0,1/28 %3.57
Hypertension,1/25 %4.0,1/28 %3.57
Thromboembolic event,0/25 %0.0,1/28 %3.57

A Phase II Study of Bevacizumab + Sorafenib in Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00632541)
 ,Single Arm A
 ,Sorafenib 200mg po daily Bevacizumab 5mg/kg every other week 1 Cycle = 4 weeks. Imaging every third cycle
Total serious adverse events,4/18 %22.22
ASCITES (NON-MALIGNANT),1/18 %5.56
DEATH NOT ASSOCIATED WITH CTCAE TERM / DISEASE PROGRESSION NOS,1/18 %5.56
NEUROPATHY: SENSORY,1/18 %5.56
PAIN / CHEST WALL,1/18 %5.56

Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC(https://clinicaltrials.gov/show/NCT00647426)
 ,Sorafenib + Docetaxel
 ,400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle Sorafenib + Docetaxel/Carboplatin: 400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
Total serious adverse events,0/7 %0.0

Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer(https://clinicaltrials.gov/show/NCT00678392)
 ,Axitinib 5 mg,Sorafenib 400 mg
 ,Axitinib (AG-013736) 5 milligram (mg) tablet administered orally twice daily in cycles of 4 weeks.,Sorafenib 400 mg tablet administered orally twice daily in cycles of 4 weeks.
Total serious adverse events,146/359 %40.67,127/355 %35.77
Anaemia,0/359 %0.0,8/355 %2.25
Splenic infarction,0/359 %0.0,1/355 %0.28
Acute coronary syndrome,0/359 %0.0,2/355 %0.56
Acute myocardial infarction,2/359 %0.56,0/355 %0.0
Angina pectoris,0/359 %0.0,2/355 %0.56
Arrhythmia supraventricular,1/359 %0.28,0/355 %0.0
Arteriosclerosis coronary artery,1/359 %0.28,0/355 %0.0
Atrial fibrillation,2/359 %0.56,0/355 %0.0
Atrial flutter,1/359 %0.28,0/355 %0.0
Atrioventricular block,0/359 %0.0,1/355 %0.28
Bradycardia,1/359 %0.28,0/355 %0.0
Cardiac arrest,1/359 %0.28,0/355 %0.0
Cardiac failure,2/359 %0.56,1/355 %0.28
Cardiopulmonary failure,2/359 %0.56,1/355 %0.28
Congestive cardiomyopathy,0/359 %0.0,1/355 %0.28
Coronary artery insufficiency,1/359 %0.28,0/355 %0.0
Haemorrhage coronary artery,1/359 %0.28,0/355 %0.0
Mitral valve incompetence,1/359 %0.28,0/355 %0.0
Myocardial infarction,6/359 %1.67,4/355 %1.13
Myocardial ischaemia,1/359 %0.28,0/355 %0.0
Prinzmetal angina,1/359 %0.28,0/355 %0.0
Supraventricular tachycardia,1/359 %0.28,0/355 %0.0
Tachycardia,0/359 %0.0,1/355 %0.28
Adrenal insufficiency,0/359 %0.0,1/355 %0.28
Hypothyroidism,1/359 %0.28,0/355 %0.0
Secondary hypothyroidism,1/359 %0.28,0/355 %0.0
Thyroiditis,0/359 %0.0,1/355 %0.28
Diplopia,1/359 %0.28,0/355 %0.0
Retinal artery embolism,0/359 %0.0,1/355 %0.28
Retinal artery occlusion,1/359 %0.28,0/355 %0.0
Retinal vein occlusion,1/359 %0.28,0/355 %0.0
Retinal vein thrombosis,1/359 %0.28,0/355 %0.0
Abdominal pain,1/359 %0.28,2/355 %0.56
Anal fistula,1/359 %0.28,0/355 %0.0
Ascites,0/359 %0.0,1/355 %0.28
Colitis ulcerative,0/359 %0.0,1/355 %0.28
Constipation,2/359 %0.56,1/355 %0.28
Diarrhoea,8/359 %2.23,5/355 %1.41
Duodenal ulcer haemorrhage,0/359 %0.0,1/355 %0.28
Enterocolitis,0/359 %0.0,1/355 %0.28
Gastric haemorrhage,2/359 %0.56,0/355 %0.0
Gastric ulcer,1/359 %0.28,0/355 %0.0
Gastritis,0/359 %0.0,1/355 %0.28
Gastrointestinal haemorrhage,0/359 %0.0,5/355 %1.41
Gastrointestinal perforation,1/359 %0.28,0/355 %0.0
Haematemesis,0/359 %0.0,1/355 %0.28
Inguinal hernia,3/359 %0.84,0/355 %0.0
Intestinal obstruction,4/359 %1.11,1/355 %0.28
Lower gastrointestinal haemorrhage,1/359 %0.28,1/355 %0.28
Melaena,1/359 %0.28,0/355 %0.0
Nausea,1/359 %0.28,1/355 %0.28
Pancreatitis,0/359 %0.0,1/355 %0.28
Rectal haemorrhage,0/359 %0.0,1/355 %0.28
Retroperitoneal haemorrhage,0/359 %0.0,1/355 %0.28
Small intestinal obstruction,1/359 %0.28,0/355 %0.0
Subileus,0/359 %0.0,1/355 %0.28
Upper gastrointestinal haemorrhage,0/359 %0.0,1/355 %0.28
Vomiting,5/359 %1.39,2/355 %0.56
Asthenia,2/359 %0.56,1/355 %0.28
Chest pain,2/359 %0.56,2/355 %0.56
Chills,1/359 %0.28,0/355 %0.0
Death,3/359 %0.84,6/355 %1.69
Device dislocation,0/359 %0.0,1/355 %0.28
Disease progression,32/359 %8.91,18/355 %5.07
Fatigue,4/359 %1.11,0/355 %0.0
General physical health deterioration,3/359 %0.84,5/355 %1.41
Hernia,1/359 %0.28,0/355 %0.0
Impaired healing,0/359 %0.0,1/355 %0.28
Inflammation,0/359 %0.0,1/355 %0.28
Malaise,1/359 %0.28,0/355 %0.0
Mucosal inflammation,1/359 %0.28,0/355 %0.0
Oedema,1/359 %0.28,0/355 %0.0
Pain,2/359 %0.56,3/355 %0.85
Pyrexia,7/359 %1.95,5/355 %1.41
Biliary dilatation,0/359 %0.0,1/355 %0.28
Budd-Chiari syndrome,1/359 %0.28,0/355 %0.0
Cholangitis,1/359 %0.28,1/355 %0.28
Cholecystitis,1/359 %0.28,1/355 %0.28
Cholelithiasis,0/359 %0.0,1/355 %0.28
Hepatic function abnormal,0/359 %0.0,1/355 %0.28
Hypersensitivity,1/359 %0.28,0/355 %0.0
Abdominal abscess,1/359 %0.28,0/355 %0.0
Appendicitis,1/359 %0.28,2/355 %0.56
Aspergillus infection,0/359 %0.0,1/355 %0.28
Bacterial diarrhoea,1/359 %0.28,0/355 %0.0
Cellulitis,0/359 %0.0,1/355 %0.28
Diverticulitis,0/359 %0.0,1/355 %0.28
Erysipelas,1/359 %0.28,0/355 %0.0
Gastroenteritis,1/359 %0.28,0/355 %0.0
Gastroenteritis viral,1/359 %0.28,0/355 %0.0
Herpes zoster,0/359 %0.0,1/355 %0.28
Infection,3/359 %0.84,0/355 %0.0
Intervertebral discitis,0/359 %0.0,1/355 %0.28
Lower respiratory tract infection,0/359 %0.0,4/355 %1.13
Lower respiratory tract infection bacterial,1/359 %0.28,0/355 %0.0
Lung infection,0/359 %0.0,1/355 %0.28
Muscle abscess,0/359 %0.0,1/355 %0.28
Pneumonia,5/359 %1.39,4/355 %1.13
Pneumonia streptococcal,1/359 %0.28,0/355 %0.0
Pneumonia viral,1/359 %0.28,0/355 %0.0
Pulmonary tuberculosis,0/359 %0.0,1/355 %0.28
Pyelonephritis,0/359 %0.0,1/355 %0.28
Respiratory tract infection,1/359 %0.28,1/355 %0.28
Sepsis,1/359 %0.28,2/355 %0.56
Septic shock,0/359 %0.0,1/355 %0.28
Urinary tract infection,2/359 %0.56,2/355 %0.56
Fall,1/359 %0.28,2/355 %0.56
Femoral neck fracture,1/359 %0.28,0/355 %0.0
Gastrointestinal anastomotic leak,1/359 %0.28,0/355 %0.0
Humerus fracture,1/359 %0.28,0/355 %0.0
Laceration,1/359 %0.28,0/355 %0.0
Lumbar vertebral fracture,2/359 %0.56,0/355 %0.0
Procedural pain,1/359 %0.28,0/355 %0.0
Radiation pneumonitis,1/359 %0.28,0/355 %0.0
Rib fracture,0/359 %0.0,1/355 %0.28
Soft tissue injury,0/359 %0.0,1/355 %0.28
Spinal compression fracture,1/359 %0.28,0/355 %0.0
Neutrophil count abnormal,1/359 %0.28,0/355 %0.0
Alanine aminotransferase increased,0/359 %0.0,1/355 %0.28
Aspartate aminotransferase increased,0/359 %0.0,1/355 %0.28
Blood alkaline phosphatase increased,0/359 %0.0,1/355 %0.28
Blood creatinine increased,2/359 %0.56,1/355 %0.28
Blood lactate dehydrogenase increased,0/359 %0.0,1/355 %0.28
C-reactive protein increased,0/359 %0.0,1/355 %0.28
Gamma-glutamyltransferase increased,0/359 %0.0,1/355 %0.28
Hepatic enzyme increased,0/359 %0.0,1/355 %0.28
Decreased appetite,3/359 %0.84,0/355 %0.0
Dehydration,10/359 %2.79,1/355 %0.28
Hypercalcaemia,1/359 %0.28,2/355 %0.56
Hyperkalaemia,2/359 %0.56,1/355 %0.28
Hypocalcaemia,0/359 %0.0,1/355 %0.28
Hypoglycaemia,1/359 %0.28,0/355 %0.0
Hypokalaemia,2/359 %0.56,0/355 %0.0
Hyponatraemia,1/359 %0.28,3/355 %0.85
Hypovolaemia,1/359 %0.28,0/355 %0.0
Arthralgia,1/359 %0.28,1/355 %0.28
Back pain,3/359 %0.84,2/355 %0.56
Flank pain,0/359 %0.0,1/355 %0.28
Musculoskeletal chest pain,0/359 %0.0,1/355 %0.28
Pain in extremity,2/359 %0.56,0/355 %0.0
Polyarthritis,0/359 %0.0,1/355 %0.28
Spinal column stenosis,0/359 %0.0,1/355 %0.28
Spondylolisthesis,0/359 %0.0,1/355 %0.28
Metastasis,1/359 %0.28,0/355 %0.0
Metastatic pain,0/359 %0.0,1/355 %0.28
Neoplasm progression,1/359 %0.28,0/355 %0.0
Renal cell carcinoma,1/359 %0.28,1/355 %0.28
Squamous cell carcinoma,0/359 %0.0,1/355 %0.28
Tumour associated fever,1/359 %0.28,0/355 %0.0
Aphasia,1/359 %0.28,0/355 %0.0
Balance disorder,0/359 %0.0,1/355 %0.28
Central nervous system haemorrhage,1/359 %0.28,0/355 %0.0
Cerebral infarction,0/359 %0.0,1/355 %0.28
Cerebral ischaemia,0/359 %0.0,1/355 %0.28
Cerebrovascular accident,2/359 %0.56,1/355 %0.28
Dizziness,3/359 %0.84,0/355 %0.0
Headache,1/359 %0.28,0/355 %0.0
Hemiparesis,0/359 %0.0,1/355 %0.28
Ischaemic stroke,0/359 %0.0,1/355 %0.28
Leukoencephalopathy,1/359 %0.28,0/355 %0.0
Loss of consciousness,2/359 %0.56,0/355 %0.0
Meningeal disorder,1/359 %0.28,0/355 %0.0
Monoplegia,0/359 %0.0,1/355 %0.28
Presyncope,1/359 %0.28,0/355 %0.0
Seizure,1/359 %0.28,0/355 %0.0
Spinal cord compression,2/359 %0.56,0/355 %0.0
Syncope,2/359 %0.56,0/355 %0.0
Transient ischaemic attack,3/359 %0.84,0/355 %0.0
Anxiety,0/359 %0.0,1/355 %0.28
Confusional state,1/359 %0.28,0/355 %0.0
Disorientation,1/359 %0.28,0/355 %0.0
Mental status changes,1/359 %0.28,1/355 %0.28
Acute kidney injury,4/359 %1.11,2/355 %0.56
Acute prerenal failure,1/359 %0.28,0/355 %0.0
Haematuria,1/359 %0.28,0/355 %0.0
Nephropathy,0/359 %0.0,1/355 %0.28
Oliguria,0/359 %0.0,1/355 %0.28
Renal failure,1/359 %0.28,0/355 %0.0
Urinary retention,1/359 %0.28,0/355 %0.0
Benign prostatic hyperplasia,1/265 %0.38,0/258 %0.0
Menometrorrhagia,0/96 %0.0,1/104 %0.96
Vaginal polyp,1/96 %1.04,0/104 %0.0
Chronic obstructive pulmonary disease,0/359 %0.0,1/355 %0.28
Cough,0/359 %0.0,1/355 %0.28
Dyspnoea,7/359 %1.95,3/355 %0.85
Dyspnoea exertional,1/359 %0.28,0/355 %0.0
Epistaxis,1/359 %0.28,1/355 %0.28
Haemoptysis,1/359 %0.28,2/355 %0.56
Haemothorax,0/359 %0.0,1/355 %0.28
Interstitial lung disease,1/359 %0.28,0/355 %0.0
Lung disorder,1/359 %0.28,0/355 %0.0
Pleural effusion,3/359 %0.84,5/355 %1.41
Pleurisy,0/359 %0.0,1/355 %0.28
Pneumothorax,4/359 %1.11,1/355 %0.28
Pneumothorax spontaneous,1/359 %0.28,0/355 %0.0
Pulmonary embolism,7/359 %1.95,1/355 %0.28
Pulmonary haemorrhage,0/359 %0.0,2/355 %0.56
Respiratory distress,1/359 %0.28,0/355 %0.0
Erythema multiforme,0/359 %0.0,3/355 %0.85
Hyperhidrosis,1/359 %0.28,0/355 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/359 %0.0,1/355 %0.28
Pustular psoriasis,0/359 %0.0,1/355 %0.28
Rash,0/359 %0.0,2/355 %0.56
Urticaria,1/359 %0.28,0/355 %0.0
Pain management,0/359 %0.0,1/355 %0.28
Vertebroplasty,0/359 %0.0,1/355 %0.28
Accelerated hypertension,1/359 %0.28,0/355 %0.0
Deep vein thrombosis,1/359 %0.28,1/355 %0.28
Hypertension,1/359 %0.28,2/355 %0.56
Hypertensive crisis,1/359 %0.28,0/355 %0.0
Hypotension,1/359 %0.28,4/355 %1.13
Infarction,0/359 %0.0,1/355 %0.28
Jugular vein thrombosis,1/359 %0.28,0/355 %0.0
Subclavian vein thrombosis,1/359 %0.28,0/355 %0.0

Sorafenib  Lenalidomide  and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma(https://clinicaltrials.gov/show/NCT00687674)
 ,Sorafenib + Lenalidomide + Dexamethasone
 
Total serious adverse events,3/13 %23.08
Pneumonia,1/13 %7.69
Leukopenia,1/13 %7.69
Rash,1/13 %7.69

Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer(https://clinicaltrials.gov/show/NCT00754923)
 ,Treatment: Sorafenib
 ,Sorafenib will be administered at a dose of 400 mg taken twice daily continuously on a 28 day cycle. sorafenib: administered orally at 400 mg taken twice daily  continuously on a 28 day cycle as an outpatient.
Total serious adverse events,1/11 %9.09
Fatigue,1/11 %9.09

Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT00813293)
 ,Sorafenib,Placebo
 ,Participants received a nine-day course of oral sorafenib 400 mg twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip 70  2 C 5 min). Sorafenib radiofrequency ablation,Participants received a nine-day course of placebo pills twice a day and radiofrequency ablation (RFA) on Day 10. Tumors in each group underwent RFA using a standard regimen (1 cm tip 70  2 C 5 min). radiofrequency ablation
Total all-cause mortality,0/9 %0.0,0/10 %0.0
Total serious adverse events,1/9 %11.11,1/10 %10.0
Liver hemorrhage,0/9 %0.0,1/10 %10.0
Leukocytes,1/9 %11.11,0/10 %0.0
Lymphopenia,1/9 %11.11,0/10 %0.0
AST SGOT,1/9 %11.11,0/10 %0.0
Bilirubin,1/9 %11.11,0/10 %0.0

Study of Sorafenib/Cetuximab in Head and Neck Cancer(https://clinicaltrials.gov/show/NCT00815295)
 ,Phase 1 - Dose Level 1,Phase 1 - Dose Level 2,Phase 2
 ,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 200 mg/m2 was administered orally twice daily.,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib 400 mg/m2 was administered orally twice daily.,Cetuximab was administered at the standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly. Sorafenib was administered orally twice daily at the MTD from Phase I.
Total serious adverse events,1/8 %12.5,1/8 %12.5,5/12 %41.67
Myocardial infarction,1/8 %12.5,0/8 %0.0,0/12 %0.0
Nausea,0/8 %0.0,1/8 %12.5,0/12 %0.0
Vomiting,0/8 %0.0,1/8 %12.5,0/12 %0.0
Death NOS,0/8 %0.0,0/8 %0.0,2/12 %16.67
General disorders and administration site conditions - Other specify,0/8 %0.0,0/8 %0.0,1/12 %8.33
Cytokine release syndrome,0/8 %0.0,0/8 %0.0,1/12 %8.33
Dehydration,0/8 %0.0,1/8 %12.5,0/12 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,0/8 %0.0,0/8 %0.0,1/12 %8.33

Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer(https://clinicaltrials.gov/show/NCT00825734)
 ,Dose Level 1a
 ,Includes patients treated at the Phase II dose - Sorafenib PO BID (400mg) Ixabepilone IV every 21 days (32mg/m^2)
Total serious adverse events,6/76 %7.89
ANEMIA,1/76 %1.32
DEATH,1/76 %1.32
INFECTION,1/76 %1.32
WEIGHT LOSS,1/76 %1.32
BACK PAIN,1/76 %1.32
ACUTE RENAL FAILURE,1/76 %1.32
DYSPNEA,2/76 %2.63
PNEUMONIA,1/76 %1.32
PALMAR-PLANTAR ERYTHRODYSESTHESIA SYNDROME,1/76 %1.32
RASH,1/76 %1.32

Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT00844883)
 ,Sorafenib and Drug Eluting Beads
 ,single arm sorafenib: sorafenib: given 400 mg twice per day for as long as it is beneficial LC Bead-TACE: LC Beads loaded with doxorubicin Doxorubicin loaded LC Beads: given intra-arterially into the liver up to fours times in a 6 month period
Total all-cause mortality,3/50 %6.0
Total serious adverse events,8/50 %16.0
Abdominal pain,1/50 %2.0
Non-cardiac chest pain,2/50 %4.0
Overdose on pain medication,1/50 %2.0
Cholangitis,1/50 %2.0
Elevated creatinine,1/50 %2.0
Tumor rupture,1/50 %2.0
Encephalopathy,1/50 %2.0

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT00862082)
 ,PR104 550 mg/m^2 + Sorafenib,PR104 770 mg/m^2 + Sorafenib
 ,550 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily),770 mg/m^2 PR104 administered IV every 4 weeks + Standard dose sorafenib (400 mg PO twice daily)
Total serious adverse events,5/8 %62.5,2/6 %33.33
Febrile neutropenia,1/8 %12.5,0/6 %0.0
Abdominal Pain,2/8 %25.0,0/6 %0.0
Decrease in general condition,1/8 %12.5,0/6 %0.0
Fatigue,0/8 %0.0,1/6 %16.67
Fever in absence of neutropenia,2/8 %25.0,0/6 %0.0
Cellulitis,1/8 %12.5,0/6 %0.0
Sepsis,0/8 %0.0,1/6 %16.67
Thrombocytopenia,1/8 %12.5,0/6 %0.0

Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall(https://clinicaltrials.gov/show/NCT00864032)
 ,Sorafenib 200/200,Sorafenib 200/400
 ,Dose level 1. Sorafenib 200 mg PO BID,Dose level 2. Sorafenib 200 mg PO Q AM and 400 mg PO Q PM
Total serious adverse events,0/3 %0.0,2/5 %40.0
rash,0/3 %0.0,2/5 %40.0

Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery(https://clinicaltrials.gov/show/NCT00875615)
 ,Cisplatin or Carboplatin + Sorafenib
 ,Cisplatin : Cisplatin 60 m/m via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles. Sorafenib : Sorafenib 400 mg po bid daily starting on Day 1 ( up to 3 days) continuously. Carboplatin : Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
Total serious adverse events,0/10 %0.0

A Study of IMC-A12 in Combination With Sorafenib in Participants With Advanced Cancer of the Liver(https://clinicaltrials.gov/show/NCT00906373)
 ,Cohort 1 - 10 mg/kg Cixutumumab,Cohort 2 - 20 mg/kg Cixutumumab
 ,Cixutumumab: 10 mg/kg administered by IV infusion on Day 1 of each 3-week cycle. Sorafenib: 400 mg administered orally twice per day on Days 1 through 21 of each 3-week cycle. Treatment cycles were repeated until there was evidence of PD toxicity or participant withdrawal.,Cixutumumab: 20 mg/kg administered by IV infusions on Day 1 of each 3-week cycle. Sorafenib: 400 mg administered orally twice per day on Days 1 through 21 of each 3-week cycle. Treatment cycles were repeated until there was evidence of PD toxicity or participant withdrawal.
Total serious adverse events,4/6 %66.67,15/41 %36.59
Retinal tear,0/6 %0.0,1/41 %2.44
Abdominal pain,0/6 %0.0,1/41 %2.44
Colitis,0/6 %0.0,1/41 %2.44
Diarrhoea,1/6 %16.67,0/41 %0.0
Gastrointestinal haemorrhage,2/6 %33.33,2/41 %4.88
Pancreatitis,1/6 %16.67,0/41 %0.0
Small intestinal perforation,0/6 %0.0,1/41 %2.44
Asthenia,0/6 %0.0,1/41 %2.44
Chest pain,0/6 %0.0,1/41 %2.44
Pyrexia,0/6 %0.0,2/41 %4.88
Bile duct stenosis,0/6 %0.0,1/41 %2.44
Cholangitis,1/6 %16.67,0/41 %0.0
Hepatic haemorrhage,0/6 %0.0,1/41 %2.44
Peritonitis,0/6 %0.0,1/41 %2.44
Peritonitis bacterial,0/6 %0.0,1/41 %2.44
Septic shock,1/6 %16.67,1/41 %2.44
Infusion related reaction,1/6 %16.67,0/41 %0.0
Spinal compression fracture,0/6 %0.0,1/41 %2.44
Blood bilirubin increased,0/6 %0.0,1/41 %2.44
Lipase increased,0/6 %0.0,1/41 %2.44
Liver function test abnormal,0/6 %0.0,1/41 %2.44
Dehydration,1/6 %16.67,0/41 %0.0
Hyperglycaemia,0/6 %0.0,2/41 %4.88
Neoplasm malignant,1/6 %16.67,2/41 %4.88
Neoplasm progression,0/6 %0.0,1/41 %2.44
Headache,0/6 %0.0,1/41 %2.44
Renal failure acute,1/6 %16.67,1/41 %2.44
Pleural effusion,0/6 %0.0,1/41 %2.44
Respiratory failure,0/6 %0.0,1/41 %2.44

Sorafenib for Patients With Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer(https://clinicaltrials.gov/show/NCT00917462)
 ,Sorafenib
 ,Sorafenib for patients with metastatic or recurrent esophageal and gastroesophageal junction cancer. Sorafenib administered orally: Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues) to avoid violation of and deviation from the protocol these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
Total all-cause mortality,35/35 %100.0
Total serious adverse events,15/35 %42.86
Sinus Tachycardia,1/35 %2.86
Constipation,1/35 %2.86
Dry Mouth,1/35 %2.86
Dysphagia,1/35 %2.86
Fistula - GI Esophagus,2/35 %5.71
Vomiting,1/35 %2.86
Constitutional Symptoms Other,1/35 %2.86
Edema: viscera,1/35 %2.86
Fatigue,2/35 %5.71
Fever,1/35 %2.86
Pain - Other,1/35 %2.86
Rigors/Chills,1/35 %2.86
Pleural Infection,1/35 %2.86
Hyperbilirubinemia,1/35 %2.86
Hypercalcemia,1/35 %2.86
Dehydration,4/35 %11.43
Pain - Chest Wall,1/35 %2.86
Pain in extremity,1/35 %2.86
Secondary malignancy,1/35 %2.86
Motor neuropathy,2/35 %5.71
Confusion,2/35 %5.71
Renal/Genitourinary - Other,1/35 %2.86
Cough,1/35 %2.86
Dyspnea,1/35 %2.86
Pleural effusion,1/35 %2.86
Pneumonitis,1/35 %2.86
Hypertension,1/35 %2.86
Thrombosis/Thrombus/Embolism,1/35 %2.86

Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer(https://clinicaltrials.gov/show/NCT00920816)
 ,Axitinib (First-line Participants),Sorafenib (First-line Participants),Axitinib (Second-line Participants),Sorafenib (Second-line Participants)
 ,Participants with no prior systemic first-line therapy received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Participants with no prior systemic first-line therapy received sorafenib tablet at a starting dose of 400 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received axitinib (AG-013736) tablet at a starting dose of 5 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.,Asian participants with prior systemic first-line therapy containing sunitinib or cytokine received sorafenib tablet at a starting dose of 400 mg orally twice daily dose adjustment was done based on the tolerability as per investigators discretion. Study medication was administered in cycles of 4 weeks.
Total serious adverse events,64/189 %33.86,24/96 %25.0,40/135 %29.63,14/69 %20.29
Anaemia,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Thrombocytopenia,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardiac failure,0/189 %0.0,0/96 %0.0,1/135 %0.74,1/69 %1.45
Myocardial infarction,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Myocardial ischaemia,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Acute myocardial infarction,0/189 %0.0,2/96 %2.08,0/135 %0.0,0/69 %0.0
Atrial flutter,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardiac arrest,3/189 %1.59,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cardio-respiratory arrest,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Abdominal pain,1/189 %0.53,3/96 %3.12,1/135 %0.74,0/69 %0.0
Anal fistula,1/189 %0.53,0/96 %0.0,0/135 %0.0,1/69 %1.45
Diarrhoea,5/189 %2.65,2/96 %2.08,2/135 %1.48,0/69 %0.0
Gastritis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Intestinal obstruction,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Oesophagitis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Upper gastrointestinal haemorrhage,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Abdominal distension,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Gastric haemorrhage,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Gastric ulcer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Gastrointestinal haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Impaired gastric emptying,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Melaena,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Nausea,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Oesophageal varices haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Peptic ulcer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Periproctitis,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Rectal haemorrhage,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Retroperitoneal haematoma,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Vomiting,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Death,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Multi-organ failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Oedema peripheral,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Disease progression,20/189 %10.58,7/96 %7.29,12/135 %8.89,5/69 %7.25
Asthenia,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Chest pain,2/189 %1.06,1/96 %1.04,0/135 %0.0,0/69 %0.0
General physical health deterioration,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Impaired healing,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Mucosal inflammation,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pyrexia,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Sudden death,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Bile duct stone,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cholangitis acute,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cholecystitis acute,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Hepatic failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Bile duct stenosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Bronchopulmonary aspergillosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Gastroenteritis,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Upper respiratory tract infection,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Anal abscess,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Pyopneumothorax,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Lung infection,1/189 %0.53,0/96 %0.0,2/135 %1.48,0/69 %0.0
Abscess,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cholecystitis infective,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Infection,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Osteomyelitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pericoronitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pneumonia,2/189 %1.06,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pyelonephritis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Sepsis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Skin bacterial infection,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Tonsillitis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Urinary tract infection,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Wound infection,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Ankle fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Facial bones fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Humerus fracture,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Multiple injuries,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Patella fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Upper limb fracture,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Wound dehiscence,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haemoglobin decreased,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Decreased appetite,1/189 %0.53,0/96 %0.0,0/135 %0.0,1/69 %1.45
Dehydration,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hyperkalaemia,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Back pain,1/189 %0.53,0/96 %0.0,1/135 %0.74,0/69 %0.0
Muscular weakness,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Pathological fracture,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Cardiac neoplasm unspecified,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cancer,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cancer metastatic,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Renal cell carcinoma,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Tumour haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Brain stem haemorrhage,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Cerebral infarction,0/189 %0.0,0/96 %0.0,2/135 %1.48,1/69 %1.45
Cerebrovascular accident,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Hemiplegia,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Loss of consciousness,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Paralysis,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Transient ischaemic attack,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Cerebral haemorrhage,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Cerebral ischaemia,2/189 %1.06,0/96 %0.0,0/135 %0.0,0/69 %0.0
Demyelinating polyneuropathy,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Paraparesis,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Paraplegia,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Spinal cord compression,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Syncope,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Renal failure,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Renal failure acute,0/189 %0.0,0/96 %0.0,2/135 %1.48,0/69 %0.0
Ureteric obstruction,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Dysuria,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haematuria,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Urinary retention,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Acute respiratory failure,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Chronic obstructive pulmonary disease,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Epistaxis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Pleural effusion,3/189 %1.59,3/96 %3.12,1/135 %0.74,0/69 %0.0
Pneumothorax,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Atelectasis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Dyspnoea,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Haemoptysis,1/189 %0.53,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pleurisy,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Pulmonary oedema,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Respiratory distress,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Respiratory failure,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Rash,0/189 %0.0,0/96 %0.0,0/135 %0.0,1/69 %1.45
Erythema multiforme,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hypotension,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Orthostatic hypotension,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Deep vein thrombosis,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Arterial haemorrhage,0/189 %0.0,0/96 %0.0,1/135 %0.74,0/69 %0.0
Aorto-duodenal fistula,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0
Circulatory collapse,0/189 %0.0,1/96 %1.04,0/135 %0.0,0/69 %0.0
Hypertensive crisis,1/189 %0.53,0/96 %0.0,0/135 %0.0,0/69 %0.0

Study to Determine the Safety  Maximum Tolerated Dose  Pharmacokinetics of Sorafenib (BAY43-9006)(https://clinicaltrials.gov/show/NCT00941863)
 ,Sorafenib 100 mg (50-mg Tablet),Sorafenib 200 mg (50-mg Tablet),Sorafenib 400 mg (50-mg Tablet),Sorafenib 400 mg (200-mg Tablet),Sorafenib 400 mg (Expansion)
 ,Dose-escalation cohort 1: Sorafenib (Nexavar BAY43-9006) 100 mg twice daily (50-mg tablet),Dose-escalation cohort 2: Sorafenib (Nexavar BAY43-9006) 200 mg twice daily (50-mg tablet),Dose-escalation cohort 3: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (50-mg tablet),Dose-escalation cohort 4: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (200-mg tablet),Dose-expansion cohort: Sorafenib (Nexavar BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
Total serious adverse events,5/7 %71.43,1/3 %33.33,8/12 %66.67,9/17 %52.94,76/119 %63.87
Neutrophils/granulocytes (ANC/AGC),0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,4/119 %3.36
Platelets,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,6/119 %5.04
Hemoglobin (HGB),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Leukocytes (total WBC),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Coagulation - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Supraventricular arrhythmias (SVT/A FIB/FLUTT),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,4/119 %3.36
Cardiovascular/arrhythmias - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Thrombosis/embolism,0/7 %0.0,0/3 %0.0,1/12 %8.33,3/17 %17.65,8/119 %6.72
Cardiac - ischemia/infarction,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Hypotension,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Pericardial effusion/pericarditis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Phlebitis (superficial),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Edema,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Cardiovascular/general - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Vomiting,0/7 %0.0,0/3 %0.0,1/12 %8.33,2/17 %11.76,8/119 %6.72
Dehydration,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,8/119 %6.72
Nausea,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,6/119 %5.04
Diarrhea patients without colostomy,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Gastrointestinal - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Anorexia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Colitis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Constipation,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Dysphagia esophagitis odynophagia (painfull swallowing),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Ileus (or neuroconstipation),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Pancreatitis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Duodenal ulcer (radiographic or endoscopic),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Fever (in absence of neutropenia),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,7/119 %5.88
Fatigue (Lethargy Malaise Asthenia),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,5/119 %4.2
Constitutional symptoms - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Pain - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,10/119 %8.4
Abdominal pain or cramping,1/7 %14.29,0/3 %0.0,1/12 %8.33,1/17 %5.88,4/119 %3.36
Chest pain (non-cardiac and nonpleuritic),1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Headache,1/7 %14.29,0/3 %0.0,1/12 %8.33,0/17 %0.0,2/119 %1.68
Tumor pain (onset/exacerb. tumor pain),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
SGPT (ALT),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
SGOT (AST),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Allergic reaction/hypersensitivity,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,0/119 %0.0
Febrile neutropenia (fever w/ unknow origin),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,12/119 %10.08
Infection without neutropenia,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,5/119 %4.2
Infection (doc clinic or microbio) w/ GR 3 or 4 Neu,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,3/119 %2.52
Infection with unknown ANC,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,2/119 %1.68
Infection/febrile neutropenia - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hyperglycemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hypokalemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Hypomagnesemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Amylase,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hypercalcemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hypoglycemia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Lipase,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Musculoskeletal - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Neurology - other,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,9/119 %7.56
Syncope (fainting),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,3/119 %2.52
CNS cerebrovascular ischemia,0/7 %0.0,1/3 %33.33,1/12 %8.33,0/17 %0.0,1/119 %0.84
Confusion,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Seizure(s),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Depressed level of consciousness,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Ataxia (incoordination),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Speech impairment (dysphasia or aphasia),1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
Neuropathy - motor,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
Neuropathy - sensory,0/7 %0.0,0/3 %0.0,1/12 %8.33,0/17 %0.0,0/119 %0.0
Renal/genitourinary - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,4/119 %3.36
Creatinine,0/7 %0.0,0/3 %0.0,1/12 %8.33,1/17 %5.88,0/119 %0.0
Ureteral obstruction,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Pleural effusion (non-malignant),0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,7/119 %5.88
Dyspnea (shortness of breath),0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,3/119 %2.52
Pulmonary - other,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,2/119 %1.68
Pneumonitis/pulmonary infiltrates,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Dermatology/skin - other,1/7 %14.29,0/3 %0.0,1/12 %8.33,0/17 %0.0,10/119 %8.4
Wound - infectious,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Wound - non-infectious,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Rash/desquamation,1/7 %14.29,0/3 %0.0,0/12 %0.0,0/17 %0.0,0/119 %0.0
CNS Hemorrhage/belleding,0/7 %0.0,0/3 %0.0,2/12 %16.67,0/17 %0.0,1/119 %0.84
Hemorrhage - other,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,3/119 %2.52
Melena/GI bleeding,0/7 %0.0,0/3 %0.0,0/12 %0.0,1/17 %5.88,1/119 %0.84
Hemoptysis,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Rectal bleeding/hematochezia,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hemorrhage/bleeding with grade 3 or 4 thrombo,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Hematuria (in absence of vaginal bleeding),0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84
Vaginal bleeding,0/7 %0.0,0/3 %0.0,0/12 %0.0,0/17 %0.0,1/119 %0.84

Depocyt With Sorafenib in Neoplastic Meningitis(https://clinicaltrials.gov/show/NCT00964743)
 ,Intrathecal DepoCyt and Oral Sorafenib
 ,This is a single arm pilot study. Investigators planned to enroll approximately 10 patients to receive concurrent intrathecal DepoCyt and oral Sorafenib. DepoCyt: through a reservoir every 2 weeks for 5 doses then every 4 weeks for an additional 5 doses (a total of 10 DepoCyt treatments). Oral Sorafenib: at 400 mg twice a day throughout the treatment course until disease progression or death.
Total serious adverse events,2/2 %100.0
Death not associated with CTCAE term - Death not otherwise specified (NOS),1/2 %50.0
Death not associated with CTCAE term - Disease progression not otherwise specified (NOS),1/2 %50.0

A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients(https://clinicaltrials.gov/show/NCT00987935)
 ,Phase I Group I Nintedanib 100 mg Bid,Phase I Group I Nintedanib 150 mg Bid,Phase I Group I Nintedanib 200 mg Bid,Phase I Group II Nintedanib 50 mg Bid,Phase I Group II Nintedanib 100 mg Bid,Phase I Group II Nintedanib 150 mg Bid,Phase I Group II Nintedanib 200 mg Bid,Phase II Nintedanib 200 mg Bid,Phase II Sorafenib 400 mg Bid
 ,Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) for the Group I patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 50 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 100 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 150 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) for the Group II patients during Phase I,Oral administration of Nintedanib (BIBF 1120) 200 mg soft gelatine capsules twice daily (bid) during Phase II,Oral administration of Sorafenib 400 mg film coated tablets twice daily (bid) during Phase II
Total serious adverse events,2/4 %50.0,1/3 %33.33,0/3 %0.0,3/3 %100.0,4/7 %57.14,1/3 %33.33,10/16 %62.5,29/63 %46.03,18/32 %56.25
Haemorrhagic anaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Thrombocytopenia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Acute coronary syndrome,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Acute myocardial infarction,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Abdominal distension,0/4 %0.0,1/3 %33.33,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Abdominal pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,1/32 %3.12
Anal fistula,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Ascites,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Diarrhoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Food poisoning,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Gastric haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Gastric perforation,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Gastric ulcer,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,0/32 %0.0
Gastroduodenitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Haematochezia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Haemorrhoids,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Nausea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Oesophageal varices haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pancreatitis acute,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Upper gastrointestinal haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,1/3 %33.33,0/16 %0.0,3/63 %4.76,1/32 %3.12
Vomiting,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Asthenia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,2/32 %6.25
Chest pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Disease progression,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Fatigue,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Malaise,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Pyrexia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,4/63 %6.35,3/32 %9.38
Cholecystitis acute,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hepatic failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,2/32 %6.25
Hepatic function abnormal,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,2/16 %12.5,0/63 %0.0,2/32 %6.25
Hepatitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hyperbilirubinaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Biliary tract infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Cellulitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Peritonitis bacterial,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Sepsis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Septic shock,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Upper respiratory tract infection,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Eye injury,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Aspartate aminotransferase increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,1/32 %3.12
Blood bilirubin increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,2/16 %12.5,1/63 %1.59,1/32 %3.12
Blood creatinine increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Blood urea increased,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Decreased appetite,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hyperkalaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hypoglycaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Hyponatraemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Back pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Musculoskeletal chest pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Pathological fracture,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,1/63 %1.59,0/32 %0.0
Hepatic cancer metastatic,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Hepatocellular carcinoma,1/4 %25.0,0/3 %0.0,0/3 %0.0,1/3 %33.33,2/7 %28.57,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Malignant neoplasm progression,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,6/63 %9.52,2/32 %6.25
Metastases to central nervous system,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,1/32 %3.12
Metastatic pain,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Nasal sinus cancer,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Tumour associated fever,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Tumour haemorrhage,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Tumour rupture,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,1/7 %14.29,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Cognitive disorder,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Headache,1/4 %25.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,0/32 %0.0
Hemiparesis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Hepatic encephalopathy,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Sciatica,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Anxiety,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Renal failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Renal failure chronic,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Dyspnoea,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,2/63 %3.17,0/32 %0.0
Pleural effusion,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonia aspiration,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Pneumonitis,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,1/16 %6.25,0/63 %0.0,0/32 %0.0
Pulmonary embolism,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,0/63 %0.0,1/32 %3.12
Respiratory failure,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0
Visceral arterial ischaemia,0/4 %0.0,0/3 %0.0,0/3 %0.0,0/3 %0.0,0/7 %0.0,0/3 %0.0,0/16 %0.0,1/63 %1.59,0/32 %0.0

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer(https://clinicaltrials.gov/show/NCT01015833)
 ,Arm I (Doxorubicin Hydrochloride Sorafenib Tosylate),Arm II (Sorafenib Tosylate)
 ,Patients receive 60 mg/m2 doxorubicin hydrochloride IV on day 1 and 400 mg sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.,Patients receive 400 mg sorafenib tosylate PO QD or BID on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Total all-cause mortality,12/167 %7.19,16/171 %9.36
Total serious adverse events,71/167 %42.51,57/171 %33.33
Anemia,9/167 %5.39,4/171 %2.34
Febrile neutropenia,7/167 %4.19,0/171 %0.0
Leukocytosis,1/167 %0.6,0/171 %0.0
Spleen disorder,0/167 %0.0,1/171 %0.58
Thrombotic thrombocytopenic purpura,0/167 %0.0,1/171 %0.58
Atrial fibrillation,3/167 %1.8,1/171 %0.58
Cardiac disorder,1/167 %0.6,0/171 %0.0
Chest pain - cardiac,0/167 %0.0,1/171 %0.58
Left ventricular systolic dysfunction,3/167 %1.8,0/171 %0.0
Myocardial infarction,1/167 %0.6,0/171 %0.0
Palpitations,1/167 %0.6,0/171 %0.0
Sinus bradycardia,0/167 %0.0,1/171 %0.58
Sinus tachycardia,1/167 %0.6,1/171 %0.58
Hypothyroidism,1/167 %0.6,1/171 %0.58
Conjunctivitis,1/167 %0.6,0/171 %0.0
Abdominal distension,0/167 %0.0,1/171 %0.58
Abdominal pain,22/167 %13.17,28/171 %16.37
Anal mucositis,1/167 %0.6,0/171 %0.0
Ascites,3/167 %1.8,2/171 %1.17
Colitis,2/167 %1.2,0/171 %0.0
Constipation,1/167 %0.6,0/171 %0.0
Diarrhea,27/167 %16.17,13/171 %7.6
Dyspepsia,1/167 %0.6,0/171 %0.0
Dysphagia,3/167 %1.8,0/171 %0.0
Esophageal ulcer,1/167 %0.6,0/171 %0.0
Esophageal varices hemorrhage,1/167 %0.6,4/171 %2.34
Esophagitis,2/167 %1.2,0/171 %0.0
Gastric hemorrhage,0/167 %0.0,2/171 %1.17
Gastrointestinal disorders - Other specify,0/167 %0.0,1/171 %0.58
Hemorrhoidal hemorrhage,0/167 %0.0,1/171 %0.58
Lower gastrointestinal hemorrhage,1/167 %0.6,0/171 %0.0
Mucositis oral,17/167 %10.18,4/171 %2.34
Nausea,34/167 %20.36,24/171 %14.04
Pancreatitis,2/167 %1.2,0/171 %0.0
Rectal hemorrhage,1/167 %0.6,0/171 %0.0
Rectal mucositis,1/167 %0.6,0/171 %0.0
Upper gastrointestinal hemorrhage,1/167 %0.6,3/171 %1.75
Vomiting,4/167 %2.4,6/171 %3.51
Death NOS,4/167 %2.4,7/171 %4.09
Edema limbs,1/167 %0.6,0/171 %0.0
Edema trunk,0/167 %0.0,1/171 %0.58
Fatigue,49/167 %29.34,32/171 %18.71
Fever,2/167 %1.2,1/171 %0.58
Localized edema,0/167 %0.0,1/171 %0.58
Multi-organ failure,1/167 %0.6,0/171 %0.0
Non-cardiac chest pain,0/167 %0.0,2/171 %1.17
Pain,1/167 %0.6,0/171 %0.0
Sudden death NOS,1/167 %0.6,2/171 %1.17
Cholecystitis,0/167 %0.0,1/171 %0.58
Gallbladder obstruction,1/167 %0.6,1/171 %0.58
Hepatic failure,3/167 %1.8,1/171 %0.58
Hepatic hemorrhage,0/167 %0.0,2/171 %1.17
Hepatobiliary disorders - Other specify,0/167 %0.0,1/171 %0.58
Anaphylaxis,1/167 %0.6,0/171 %0.0
Abdominal infection,0/167 %0.0,1/171 %0.58
Bone infection,1/167 %0.6,1/171 %0.58
Infections and infestations - Other specify,3/167 %1.8,1/171 %0.58
Lung infection,6/167 %3.59,0/171 %0.0
Peritoneal infection,1/167 %0.6,1/171 %0.58
Rash pustular,1/167 %0.6,0/171 %0.0
Sepsis,5/167 %2.99,2/171 %1.17
Skin infection,2/167 %1.2,2/171 %1.17
Urinary tract infection,1/167 %0.6,0/171 %0.0
Wound infection,0/167 %0.0,1/171 %0.58
Fall,0/167 %0.0,2/171 %1.17
Fracture,0/167 %0.0,1/171 %0.58
Wound complication,1/167 %0.6,0/171 %0.0
Activated partial thromboplastin time prolonged,0/167 %0.0,1/171 %0.58
Alanine aminotransferase increased,3/167 %1.8,3/171 %1.75
Alkaline phosphatase increased,3/167 %1.8,4/171 %2.34
Aspartate aminotransferase increased,4/167 %2.4,6/171 %3.51
Blood bilirubin increased,8/167 %4.79,7/171 %4.09
Creatinine increased,3/167 %1.8,0/171 %0.0
Ejection fraction decreased,3/167 %1.8,1/171 %0.58
Haptoglobin decreased,1/167 %0.6,0/171 %0.0
INR increased,2/167 %1.2,1/171 %0.58
Leukocyte count decreased,1/167 %0.6,0/171 %0.0
Lipase increased,1/167 %0.6,0/171 %0.0
Lymphocyte count decreased,6/167 %3.59,2/171 %1.17
Neutrophil count decreased,31/167 %18.56,0/171 %0.0
Platelet count decreased,35/167 %20.96,20/171 %11.7
Weight loss,2/167 %1.2,1/171 %0.58
White blood cell decreased,10/167 %5.99,0/171 %0.0
Anorexia,5/167 %2.99,4/171 %2.34
Dehydration,14/167 %8.38,5/171 %2.92
Hyperglycemia,2/167 %1.2,2/171 %1.17
Hyperkalemia,4/167 %2.4,1/171 %0.58
Hypernatremia,0/167 %0.0,1/171 %0.58
Hypoalbuminemia,4/167 %2.4,1/171 %0.58
Hypokalemia,2/167 %1.2,0/171 %0.0
Hypomagnesemia,0/167 %0.0,1/171 %0.58
Hyponatremia,10/167 %5.99,4/171 %2.34
Hypophosphatemia,4/167 %2.4,1/171 %0.58
Metabolism and nutrition disorders - Other specify,0/167 %0.0,1/171 %0.58
Serum phosphate decreased,1/167 %0.6,0/171 %0.0
Back pain,1/167 %0.6,1/171 %0.58
Bone pain,0/167 %0.0,1/171 %0.58
Generalized muscle weakness,1/167 %0.6,1/171 %0.58
Myalgia,1/167 %0.6,0/171 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,1/167 %0.6,3/171 %1.75
Treatment related secondary malignancy,2/167 %1.2,0/171 %0.0
Amnesia,1/167 %0.6,0/171 %0.0
Headache,0/167 %0.0,1/171 %0.58
Intracranial hemorrhage,0/167 %0.0,1/171 %0.58
Nervous system disorders - Other specify,1/167 %0.6,0/171 %0.0
Seizure,0/167 %0.0,1/171 %0.58
Syncope vasovagal,1/167 %0.6,0/171 %0.0
Anxiety,1/167 %0.6,1/171 %0.58
Confusion,1/167 %0.6,2/171 %1.17
Acute kidney injury,1/167 %0.6,0/171 %0.0
Hematuria,2/167 %1.2,1/171 %0.58
Urogenital disorder,1/167 %0.6,0/171 %0.0
Dyspnea,4/167 %2.4,4/171 %2.34
Epistaxis,1/167 %0.6,3/171 %1.75
Hypoxia,1/167 %0.6,1/171 %0.58
Pulmonary edema,0/167 %0.0,1/171 %0.58
Sore throat,1/167 %0.6,0/171 %0.0
Alopecia,2/167 %1.2,0/171 %0.0
Erythema multiforme,1/167 %0.6,0/171 %0.0
Palmar-plantar erythrodysesthesia syndrome,13/167 %7.78,10/171 %5.85
Pruritus,1/167 %0.6,0/171 %0.0
Rash maculo-papular,1/167 %0.6,2/171 %1.17
Scalp pain,0/167 %0.0,1/171 %0.58
Skin ulceration,3/167 %1.8,3/171 %1.75
Stevens-Johnson syndrome,1/167 %0.6,0/171 %0.0
Hypertension,21/167 %12.57,16/171 %9.36
Hypotension,2/167 %1.2,1/171 %0.58
Thromboembolic event,0/167 %0.0,3/171 %1.75

Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01032850)
 ,Arm 1: Sorafenib & Capecitabine
 ,Intervention: Sorafenib & Capecitabine: Sorafenib twice a day by mouth (400 mg) Capecitabine twice a day by mouth (850 mg) Sorafenib & Capecitabine: Intervention: Sorafenib twice a day by mouth (400 mg) Capecitabine twice a day by mouth (850 mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
Total serious adverse events,2/13 %15.38
Nausea,1/13 %7.69
Vomiting,1/13 %7.69
Fatigue,1/13 %7.69
Fever,1/13 %7.69
Death,1/13 %7.69
Hyponatremia (Low sodium levels),1/13 %7.69
Anorexia (lack of appetite),1/13 %7.69
Dehydration,1/13 %7.69
Weakness,1/13 %7.69

Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced  Unresectable  or Metastatic Gallbladder Cancer or Cholangiocarcinoma(https://clinicaltrials.gov/show/NCT01093222)
 ,Sorafenib and Erlotinib
 ,Patients receive sorafenib tosylate 400 mg PO twice daily and erlotinib hydrochloride 100 mg PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Total serious adverse events,17/34 %50.0
Cardiac arrest,1/34 %2.94
Abdominal pain,4/34 %11.76
Ascites,1/34 %2.94
Diarrhea,1/34 %2.94
Duodenal ulcer,1/34 %2.94
Gastric perforation,1/34 %2.94
Gastritis,1/34 %2.94
Gastrointestinal disorders - Other specify,1/34 %2.94
Nausea,3/34 %8.82
Small intestinal obstruction,1/34 %2.94
Vomiting,2/34 %5.88
Death NOS,6/34 %17.65
Multi-organ failure,1/34 %2.94
Bile duct stenosis,1/34 %2.94
Gallbladder obstruction,1/34 %2.94
Hepatic necrosis,1/34 %2.94
Hepatobiliary disorders - Other specify,1/34 %2.94
Allergic reaction,1/34 %2.94
Device related infection,1/34 %2.94
Hepatic infection,1/34 %2.94
Lung infection,1/34 %2.94
Sepsis,3/34 %8.82
Alanine aminotransferase increased,1/34 %2.94
Alkaline phosphatase increased,2/34 %5.88
Aspartate aminotransferase increased,2/34 %5.88
Blood bilirubin increased,4/34 %11.76
Dehydration,2/34 %5.88
Hypoalbuminemia,2/34 %5.88
Generalized muscle weakness,1/34 %2.94
Neoplasms benign malignant and unspecified - Other,1/34 %2.94
Dizziness,1/34 %2.94
Lethargy,1/34 %2.94
Dyspnea,1/34 %2.94
Erythema multiforme,1/34 %2.94
Hypertension,1/34 %2.94

Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma(https://clinicaltrials.gov/show/NCT01100242)
 ,VELCADE and Sorafenib
 ,VELCADE (bortezomib) 1mg/m2 intravenously on days 148 & 11 and sorafenib at 200 mg orally twice per day. One full course is comprised of 21 days.
Total serious adverse events,6/17 %35.29
Chest pain,1/17 %5.88
Pain - other,1/17 %5.88
Pancreatitis,1/17 %5.88
Infection - Other,1/17 %5.88
Seizure,1/17 %5.88
Urinary retention,1/17 %5.88
Dyspnea (Shortness of breath),1/17 %5.88

A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib(https://clinicaltrials.gov/show/NCT01140347)
 ,Ramucirumab (IMC-1121B) + BSC,Placebo + BSC
 ,Ramucirumab 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.,Placebo: 8 mg/kg IV infusion every 2 weeks. BSC: Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
Total serious adverse events,124/277 %44.77,92/276 %33.33
Anaemia,0/277 %0.0,2/276 %0.72
Disseminated intravascular coagulation,1/277 %0.36,0/276 %0.0
Neutropenia,1/277 %0.36,0/276 %0.0
Thrombocytopenia,1/277 %0.36,0/276 %0.0
Cardiac failure,0/277 %0.0,1/276 %0.36
Pericardial effusion,1/277 %0.36,0/276 %0.0
Supraventricular tachycardia,1/277 %0.36,0/276 %0.0
Retinal detachment,1/277 %0.36,0/276 %0.0
Abdominal distension,1/277 %0.36,1/276 %0.36
Abdominal pain,6/277 %2.17,9/276 %3.26
Abdominal pain upper,0/277 %0.0,1/276 %0.36
Ascites,8/277 %2.89,3/276 %1.09
Colitis,0/277 %0.0,1/276 %0.36
Diarrhoea,1/277 %0.36,0/276 %0.0
Duodenal ulcer,1/277 %0.36,0/276 %0.0
Dysphagia,1/277 %0.36,0/276 %0.0
Food poisoning,1/277 %0.36,0/276 %0.0
Gastric antral vascular ectasia,1/277 %0.36,0/276 %0.0
Gastric haemorrhage,1/277 %0.36,1/276 %0.36
Gastric varices haemorrhage,1/277 %0.36,0/276 %0.0
Gastroduodenitis,1/277 %0.36,0/276 %0.0
Gastrointestinal haemorrhage,7/277 %2.53,0/276 %0.0
Haemorrhoids,0/277 %0.0,1/276 %0.36
Ileus,0/277 %0.0,1/276 %0.36
Inguinal hernia,0/277 %0.0,1/276 %0.36
Intestinal obstruction,0/277 %0.0,1/276 %0.36
Irritable bowel syndrome,1/277 %0.36,0/276 %0.0
Large intestine perforation,1/277 %0.36,0/276 %0.0
Melaena,0/277 %0.0,1/276 %0.36
Nausea,2/277 %0.72,1/276 %0.36
Oesophageal haemorrhage,1/277 %0.36,1/276 %0.36
Oesophageal varices haemorrhage,4/277 %1.44,10/276 %3.62
Pancreatitis,0/277 %0.0,1/276 %0.36
Peritoneal haemorrhage,1/277 %0.36,0/276 %0.0
Small intestinal obstruction,0/277 %0.0,1/276 %0.36
Umbilical hernia,1/277 %0.36,0/276 %0.0
Upper gastrointestinal haemorrhage,2/277 %0.72,1/276 %0.36
Varices oesophageal,1/277 %0.36,0/276 %0.0
Vomiting,1/277 %0.36,1/276 %0.36
Asthenia,4/277 %1.44,1/276 %0.36
Chills,1/277 %0.36,0/276 %0.0
Death,1/277 %0.36,0/276 %0.0
Extravasation,0/277 %0.0,1/276 %0.36
Fatigue,1/277 %0.36,2/276 %0.72
General physical health deterioration,9/277 %3.25,3/276 %1.09
Generalised oedema,1/277 %0.36,0/276 %0.0
Hernia obstructive,1/277 %0.36,0/276 %0.0
Hyperthermia,1/277 %0.36,0/276 %0.0
Malaise,0/277 %0.0,1/276 %0.36
Multi-organ failure,2/277 %0.72,1/276 %0.36
Non-cardiac chest pain,1/277 %0.36,1/276 %0.36
Oedema,0/277 %0.0,2/276 %0.72
Oedema peripheral,2/277 %0.72,1/276 %0.36
Pyrexia,7/277 %2.53,3/276 %1.09
Sudden death,1/277 %0.36,0/276 %0.0
Acute hepatic failure,1/277 %0.36,0/276 %0.0
Bile duct stone,1/277 %0.36,1/276 %0.36
Cholangitis,5/277 %1.81,1/276 %0.36
Cholangitis acute,1/277 %0.36,1/276 %0.36
Hepatic cirrhosis,1/277 %0.36,1/276 %0.36
Hepatic failure,6/277 %2.17,5/276 %1.81
Hepatic function abnormal,0/277 %0.0,1/276 %0.36
Hepatorenal syndrome,4/277 %1.44,1/276 %0.36
Hyperbilirubinaemia,1/277 %0.36,3/276 %1.09
Hypertransaminasaemia,1/277 %0.36,0/276 %0.0
Jaundice,1/277 %0.36,1/276 %0.36
Jaundice cholestatic,0/277 %0.0,2/276 %0.72
Liver disorder,1/277 %0.36,0/276 %0.0
Portal vein thrombosis,1/277 %0.36,1/276 %0.36
Anaphylactic reaction,2/277 %0.72,0/276 %0.0
Anal abscess,2/277 %0.72,0/276 %0.0
Bacteraemia,1/277 %0.36,0/276 %0.0
Campylobacter infection,1/277 %0.36,0/276 %0.0
Candida sepsis,1/277 %0.36,0/276 %0.0
Device related infection,1/277 %0.36,0/276 %0.0
Device related sepsis,1/277 %0.36,0/276 %0.0
Infection,1/277 %0.36,0/276 %0.0
Influenza,0/277 %0.0,1/276 %0.36
Liver abscess,1/277 %0.36,0/276 %0.0
Lobar pneumonia,1/277 %0.36,0/276 %0.0
Lung infection,2/277 %0.72,0/276 %0.0
Peritonitis,1/277 %0.36,1/276 %0.36
Peritonitis bacterial,1/277 %0.36,0/276 %0.0
Pneumonia,3/277 %1.08,3/276 %1.09
Pneumonia bacterial,1/277 %0.36,0/276 %0.0
Pneumonia klebsiella,0/277 %0.0,1/276 %0.36
Pulmonary sepsis,1/277 %0.36,0/276 %0.0
Sepsis,3/277 %1.08,2/276 %0.72
Septic shock,0/277 %0.0,1/276 %0.36
Upper respiratory tract infection,1/277 %0.36,1/276 %0.36
Urinary tract infection,3/277 %1.08,0/276 %0.0
Fall,0/277 %0.0,1/276 %0.36
Femur fracture,0/277 %0.0,1/276 %0.36
Infusion related reaction,1/277 %0.36,0/276 %0.0
Aspartate aminotransferase increased,0/277 %0.0,1/276 %0.36
Blood bilirubin increased,2/277 %0.72,0/276 %0.0
Blood creatinine increased,1/277 %0.36,0/276 %0.0
General physical condition abnormal,1/277 %0.36,0/276 %0.0
Liver function test abnormal,1/277 %0.36,0/276 %0.0
Cachexia,1/277 %0.36,1/276 %0.36
Decreased appetite,3/277 %1.08,0/276 %0.0
Dehydration,2/277 %0.72,1/276 %0.36
Diabetes mellitus,1/277 %0.36,0/276 %0.0
Hypercalcaemia,1/277 %0.36,1/276 %0.36
Hyperglycaemia,0/277 %0.0,2/276 %0.72
Hyperkalaemia,1/277 %0.36,0/276 %0.0
Hypertriglyceridaemia,1/277 %0.36,0/276 %0.0
Hypocalcaemia,1/277 %0.36,0/276 %0.0
Hypoglycaemia,0/277 %0.0,1/276 %0.36
Hyponatraemia,1/277 %0.36,1/276 %0.36
Arthritis,1/277 %0.36,0/276 %0.0
Back pain,0/277 %0.0,4/276 %1.45
Flank pain,0/277 %0.0,1/276 %0.36
Musculoskeletal chest pain,0/277 %0.0,1/276 %0.36
Neck pain,1/277 %0.36,0/276 %0.0
Pathological fracture,1/277 %0.36,0/276 %0.0
Spinal pain,0/277 %0.0,1/276 %0.36
Liver carcinoma ruptured,2/277 %0.72,2/276 %0.72
Malignant neoplasm progression,23/277 %8.3,16/276 %5.8
Metastases to bone,1/277 %0.36,1/276 %0.36
Metastases to central nervous system,1/277 %0.36,0/276 %0.0
Metastases to lung,1/277 %0.36,0/276 %0.0
Small intestine adenocarcinoma,0/277 %0.0,1/276 %0.36
Tumour associated fever,1/277 %0.36,0/276 %0.0
Tumour pain,0/277 %0.0,4/276 %1.45
Central nervous system lesion,1/277 %0.36,0/276 %0.0
Cerebral infarction,0/277 %0.0,1/276 %0.36
Coma hepatic,1/277 %0.36,0/276 %0.0
Convulsion,2/277 %0.72,0/276 %0.0
Diplegia,1/277 %0.36,0/276 %0.0
Dizziness,1/277 %0.36,1/276 %0.36
Encephalopathy,1/277 %0.36,0/276 %0.0
Hepatic encephalopathy,12/277 %4.33,1/276 %0.36
Mental impairment,1/277 %0.36,0/276 %0.0
Peripheral motor neuropathy,0/277 %0.0,1/276 %0.36
Somnolence,1/277 %0.36,0/276 %0.0
Spinal cord compression,1/277 %0.36,0/276 %0.0
Subarachnoid haemorrhage,0/277 %0.0,1/276 %0.36
Tongue biting,0/277 %0.0,1/276 %0.36
Mental status changes,0/277 %0.0,1/276 %0.36
Renal failure,2/277 %0.72,0/276 %0.0
Renal failure acute,3/277 %1.08,1/276 %0.36
Renal impairment,1/277 %0.36,0/276 %0.0
Acute respiratory distress syndrome,0/277 %0.0,1/276 %0.36
Dyspnoea,1/277 %0.36,2/276 %0.72
Haemoptysis,2/277 %0.72,1/276 %0.36
Hypoxia,1/277 %0.36,0/276 %0.0
Pleural effusion,2/277 %0.72,3/276 %1.09
Pneumonitis,0/277 %0.0,1/276 %0.36
Pulmonary embolism,1/277 %0.36,2/276 %0.72
Pulmonary haemorrhage,0/277 %0.0,1/276 %0.36
Dermatitis allergic,1/277 %0.36,0/276 %0.0
Skin lesion,1/277 %0.36,0/276 %0.0
Skin ulcer,1/277 %0.36,0/276 %0.0
Deep vein thrombosis,2/277 %0.72,0/276 %0.0
Haemorrhage,0/277 %0.0,1/276 %0.36
Hypertension,1/277 %0.36,0/276 %0.0
Shock haemorrhagic,1/277 %0.36,0/276 %0.0

Sorafenib Dose Ramp-Up in Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT01203787)
 ,Sorafenib Standard Dosing Regimen,Sorafenib Ramp-Up Regimen
 ,Sorafenib 400 mg (2 tablets of 200 mg) twice daily until end of treatment or week 24,200 mg daily from Day 0-Day 13 200 mg twice daily from Day 14-Day 20 600 mg daily from Day 21-Day 27 400 mg twice daily beginning Day 28 until end of treatment or Week 24
Total serious adverse events,16/63 %25.4,13/57 %22.81
Anemia,2/63 %3.17,0/57 %0.0
Thrombocytopenia,1/63 %1.59,0/57 %0.0
Acute congestive heart failure,1/63 %1.59,0/57 %0.0
Chest pain,1/63 %1.59,0/57 %0.0
Cardiac arrest,1/63 %1.59,0/57 %0.0
Hypertension,0/63 %0.0,1/57 %1.75
Hypotension,3/63 %4.76,0/57 %0.0
Blurred vision,0/63 %0.0,1/57 %1.75
Abdominal pain,1/63 %1.59,0/57 %0.0
Nausea,1/63 %1.59,0/57 %0.0
Upper gastrointestinal bleed,1/63 %1.59,2/57 %3.51
Vomiting,1/63 %1.59,0/57 %0.0
Deterioration of condition,0/63 %0.0,1/57 %1.75
Hypothermia,1/63 %1.59,0/57 %0.0
Syncopal episode,1/63 %1.59,0/57 %0.0
Ascites,1/63 %1.59,1/57 %1.75
Biliary obstruction,1/63 %1.59,0/57 %0.0
Decompensated liver failure,1/63 %1.59,0/57 %0.0
Encephalopathy,6/63 %9.52,1/57 %1.75
Liver failure,0/63 %0.0,4/57 %7.02
Cellulitis,1/63 %1.59,0/57 %0.0
Influenza,1/63 %1.59,0/57 %0.0
Meningitis,1/63 %1.59,0/57 %0.0
Pneumonia,1/63 %1.59,1/57 %1.75
Sepsis,2/63 %3.17,1/57 %1.75
Spontaneous bacterial perotinitis,1/63 %1.59,0/57 %0.0
Urinary tract infection,0/63 %0.0,1/57 %1.75
Drug toxicity,1/63 %1.59,0/57 %0.0
Post-embolization syndrome,3/63 %4.76,0/57 %0.0
Dehydration,2/63 %3.17,1/57 %1.75
Failure to thrive,1/63 %1.59,0/57 %0.0
Rib fracture,1/63 %1.59,0/57 %0.0
Dizziness,1/63 %1.59,0/57 %0.0
Vertigo,0/63 %0.0,1/57 %1.75
Unsteady gait,0/63 %0.0,1/57 %1.75
Acute renal failure,3/63 %4.76,0/57 %0.0
Pleural effusion,1/63 %1.59,1/57 %1.75
Pulmonary embolism,1/63 %1.59,0/57 %0.0
Respiratory failure,2/63 %3.17,1/57 %1.75
Abrasion,1/63 %1.59,0/57 %0.0

ABT-888 and Temozolomide for Liver Cancer(https://clinicaltrials.gov/show/NCT01205828)
 ,Temozolomide + ABT-888
 ,Temozolomide and ABT-888 temozolomide + ABT-888: Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days ABT-888 40 mg BID PO Days 1-7 every 28 days Patents with stable disease or continued response to therapy will be treated and followed for a total of 6 cycles (6 months).
Total serious adverse events,6/16 %37.5
nausea vomit,3/16 %18.75
bleeding,1/16 %6.25
fatigue,1/16 %6.25
multiorgan failure,1/16 %6.25

Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer(https://clinicaltrials.gov/show/NCT01234337)
 ,Sorafenib (Nexavar BAY43-9006) + Capecitabine,Placebo + Capecitabine
 ,Sorafenib tablets were administered orally continuously at a total daily dose of 600 mg (200 mg in the morning 400 mg in the evening) in a 3-week cycle. Capecitabine was administered orally at a total daily dose of 2000 mg/m^2 (1000 mg/m^2 twice daily 12 hours apart). If tolerability criteria were met for a subject capecitabine dose was escalated to 2500 mg/m^2 total daily dose (1250 mg/m^2 twice daily) and sorafenib dose to a total daily dose of 800 mg for that subject.,Placebo tablets matching with sorafenib were administered orally continuously (1 tablet in the morning 2 tablets in the evening) in a 3-week cycle. Capecitabine was administered orally at a total daily dose of 2000 mg/m^2 (1000 mg/m^2 twice daily 12 hours apart). If tolerability criteria were met for a subject capecitabine dose was escalated to 2500 mg/m^2 total daily dose (1250 mg/m^2 twice daily) and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
Total serious adverse events,80/260 %30.77,71/267 %26.59
Anaemia,2/260 %0.77,2/267 %0.75
Febrile neutropenia,0/260 %0.0,1/267 %0.37
Neutropenia,2/260 %0.77,0/267 %0.0
Thrombocytopenia,0/260 %0.0,1/267 %0.37
Bundle branch block right,0/260 %0.0,1/267 %0.37
Pericardial effusion,0/260 %0.0,5/267 %1.87
Cardiopulmonary failure,0/260 %0.0,1/267 %0.37
Aplasia,0/260 %0.0,1/267 %0.37
Eye symptom,1/260 %0.38,0/267 %0.0
Abdominal discomfort,0/260 %0.0,1/267 %0.37
Abdominal pain,2/260 %0.77,1/267 %0.37
Acute abdomen,1/260 %0.38,0/267 %0.0
Ascites,1/260 %0.38,2/267 %0.75
Colitis,1/260 %0.38,2/267 %0.75
Constipation,1/260 %0.38,0/267 %0.0
Diarrhoea,3/260 %1.15,8/267 %3.0
Enteritis,0/260 %0.0,1/267 %0.37
Melaena,1/260 %0.38,0/267 %0.0
Nausea,3/260 %1.15,2/267 %0.75
Oesophageal stenosis,1/260 %0.38,0/267 %0.0
Pancreatitis,1/260 %0.38,0/267 %0.0
Swollen tongue,1/260 %0.38,0/267 %0.0
Vomiting,7/260 %2.69,1/267 %0.37
Duodenal stenosis,1/260 %0.38,0/267 %0.0
Subileus,0/260 %0.0,1/267 %0.37
Neutropenic colitis,0/260 %0.0,3/267 %1.12
Death,2/260 %0.77,1/267 %0.37
Fatigue,2/260 %0.77,2/267 %0.75
Mucosal inflammation,1/260 %0.38,0/267 %0.0
Pain,2/260 %0.77,0/267 %0.0
Pyrexia,0/260 %0.0,3/267 %1.12
General physical health deterioration,3/260 %1.15,3/267 %1.12
Gallbladder pain,1/260 %0.38,0/267 %0.0
Hepatic failure,2/260 %0.77,1/267 %0.37
Hyperbilirubinaemia,1/260 %0.38,0/267 %0.0
Jaundice cholestatic,1/260 %0.38,0/267 %0.0
Bronchitis,1/260 %0.38,0/267 %0.0
Gastroenteritis viral,1/260 %0.38,0/267 %0.0
Pneumonia,2/260 %0.77,0/267 %0.0
Sepsis,2/260 %0.77,0/267 %0.0
Urinary tract infection,2/260 %0.77,1/267 %0.37
Cytomegalovirus enterocolitis,1/260 %0.38,0/267 %0.0
Lung infection,2/260 %0.77,0/267 %0.0
Femoral neck fracture,1/260 %0.38,0/267 %0.0
Femur fracture,1/260 %0.38,1/267 %0.37
Hip fracture,0/260 %0.0,1/267 %0.37
Humerus fracture,0/260 %0.0,1/267 %0.37
Tendon rupture,0/260 %0.0,1/267 %0.37
Wrist fracture,1/260 %0.38,0/267 %0.0
Biopsy lung,1/260 %0.38,0/267 %0.0
Blood bilirubin increased,0/260 %0.0,1/267 %0.37
White blood cell count decreased,1/260 %0.38,0/267 %0.0
Dehydration,2/260 %0.77,0/267 %0.0
Hypercalcaemia,0/260 %0.0,2/267 %0.75
Hyperglycaemia,0/260 %0.0,1/267 %0.37
Hypoglycaemia,0/260 %0.0,1/267 %0.37
Hypokalaemia,1/260 %0.38,4/267 %1.5
Hyponatraemia,1/260 %0.38,0/267 %0.0
Hypophosphataemia,0/260 %0.0,1/267 %0.37
Arthralgia,3/260 %1.15,1/267 %0.37
Back pain,2/260 %0.77,0/267 %0.0
Bone pain,0/260 %0.0,1/267 %0.37
Musculoskeletal pain,0/260 %0.0,1/267 %0.37
Myopathy,1/260 %0.38,0/267 %0.0
Mobility decreased,0/260 %0.0,1/267 %0.37
Musculoskeletal chest pain,1/260 %0.38,0/267 %0.0
Breast cancer,0/260 %0.0,1/267 %0.37
Malignant pleural effusion,1/260 %0.38,0/267 %0.0
Metastases to liver,0/260 %0.0,1/267 %0.37
Metastases to spine,0/260 %0.0,1/267 %0.37
Metastases to meninges,0/260 %0.0,1/267 %0.37
Tumour associated fever,1/260 %0.38,0/267 %0.0
Breast cancer metastatic,1/260 %0.38,2/267 %0.75
Cancer pain,1/260 %0.38,0/267 %0.0
Metastases to central nervous system,1/260 %0.38,0/267 %0.0
Disturbance in attention,1/260 %0.38,0/267 %0.0
Dizziness,0/260 %0.0,1/267 %0.37
Epilepsy,1/260 %0.38,0/267 %0.0
Facial paralysis,0/260 %0.0,1/267 %0.37
Headache,2/260 %0.77,1/267 %0.37
Hepatic encephalopathy,1/260 %0.38,1/267 %0.37
Lethargy,0/260 %0.0,1/267 %0.37
Neuralgia,1/260 %0.38,0/267 %0.0
Presyncope,1/260 %0.38,0/267 %0.0
Sciatica,1/260 %0.38,0/267 %0.0
Spinal cord compression,0/260 %0.0,1/267 %0.37
Brain oedema,0/260 %0.0,1/267 %0.37
Central nervous system mass,0/260 %0.0,1/267 %0.37
Cytotoxic oedema,1/260 %0.38,0/267 %0.0
Confusional state,1/260 %0.38,0/267 %0.0
Hydronephrosis,1/260 %0.38,1/267 %0.37
Renal colic,1/260 %0.38,0/267 %0.0
Acute kidney injury,1/260 %0.38,0/267 %0.0
Menorrhagia,1/260 %0.38,0/267 %0.0
Asphyxia,1/260 %0.38,0/267 %0.0
Bronchospasm,1/260 %0.38,0/267 %0.0
Dyspnoea,8/260 %3.08,3/267 %1.12
Haemoptysis,0/260 %0.0,1/267 %0.37
Pleural effusion,6/260 %2.31,11/267 %4.12
Pneumonitis,1/260 %0.38,0/267 %0.0
Pneumothorax,1/260 %0.38,3/267 %1.12
Pulmonary embolism,3/260 %1.15,4/267 %1.5
Pulmonary microemboli,1/260 %0.38,0/267 %0.0
Respiratory failure,3/260 %1.15,0/267 %0.0
Tracheal obstruction extrinsic,1/260 %0.38,0/267 %0.0
Erythema multiforme,1/260 %0.38,0/267 %0.0
Palmar-plantar erythrodysaesthesia syndrome,0/260 %0.0,1/267 %0.37
Rash,1/260 %0.38,0/267 %0.0
Cholecystectomy,0/260 %0.0,1/267 %0.37
Hysterectomy,1/260 %0.38,0/267 %0.0
Pleurodesis,2/260 %0.77,0/267 %0.0
Central venous catheterisation,1/260 %0.38,0/267 %0.0
Hepatectomy,1/260 %0.38,0/267 %0.0
Axillary lymphadenectomy,1/260 %0.38,0/267 %0.0
Cancer surgery,0/260 %0.0,1/267 %0.37
Lymphoedema,1/260 %0.38,0/267 %0.0
Superior vena cava syndrome,1/260 %0.38,0/267 %0.0
Deep vein thrombosis,1/260 %0.38,3/267 %1.12
Peripheral artery occlusion,1/260 %0.38,0/267 %0.0
Venous thrombosis limb,0/260 %0.0,1/267 %0.37

Study of Mapatumumab in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01258608)
 ,Sorafenib+Placebo,Sorafenib+Mapatumumab 30 mg/kg
 ,Participants received sorafenib 400 milligrams (mg) orally twice daily continuously in each 21-day cycle. Placebo was administered via the intravenous route on Day 1 of each 21-day cycle. The treatments were administered until radiologic disease progression or unacceptable toxicity.,Participants received sorafenib 400 mg orally twice daily continuously in each 21-day cycle. Mapatumumab 30 milligrams per kilogram (mg/kg) was administered via the intravenous route on Day 1 of each 21-day cycle. The treatments were administered until radiologic disease progression or unacceptable toxicity.
Total all-cause mortality,40/51 %78.43,39/50 %78.0
Total serious adverse events,27/51 %52.94,21/50 %42.0
Disseminated intravascular coagulation,0/51 %0.0,1/50 %2.0
Acute myocardial infarction,0/51 %0.0,2/50 %4.0
Cardio-respiratory arrest,0/51 %0.0,1/50 %2.0
Myocardial ischaemia,0/51 %0.0,1/50 %2.0
Atrial fibrillation,1/51 %1.96,0/50 %0.0
Atrial flutter,1/51 %1.96,0/50 %0.0
Atrioventricular block,1/51 %1.96,0/50 %0.0
Oesophageal varices haemorrhage,0/51 %0.0,3/50 %6.0
Gastric haemorrhage,2/51 %3.92,1/50 %2.0
Upper gastrointestinal haemorrhage,2/51 %3.92,1/50 %2.0
Food poisoning,0/51 %0.0,1/50 %2.0
Ascites,1/51 %1.96,0/50 %0.0
Gastric ulcer,1/51 %1.96,0/50 %0.0
Gastric ulcer haemorrhage,1/51 %1.96,0/50 %0.0
General physical health deterioration,2/51 %3.92,1/50 %2.0
Disease progression,1/51 %1.96,0/50 %0.0
Fatigue,1/51 %1.96,0/50 %0.0
Hepatic failure,0/51 %0.0,3/50 %6.0
Hyperbilirubinaemia,1/51 %1.96,0/50 %0.0
Appendicitis,0/51 %0.0,1/50 %2.0
Gangrene,0/51 %0.0,1/50 %2.0
Oesophageal candidiasis,0/51 %0.0,1/50 %2.0
Device related infection,1/51 %1.96,0/50 %0.0
Craniocerebral injury,1/51 %1.96,1/50 %2.0
Road traffic accident,0/51 %0.0,1/50 %2.0
Gamma-glutamyltransferase increased,3/51 %5.88,0/50 %0.0
Blood bilirubin increased,1/51 %1.96,2/50 %4.0
Alanine aminotransferase increased,0/51 %0.0,1/50 %2.0
Lipase increased,1/51 %1.96,0/50 %0.0
Hyperkalaemia,1/51 %1.96,2/50 %4.0
Dehydration,0/51 %0.0,1/50 %2.0
Malnutrition,0/51 %0.0,1/50 %2.0
Cachexia,1/51 %1.96,0/50 %0.0
Hyponatraemia,1/51 %1.96,0/50 %0.0
Arthritis,1/51 %1.96,0/50 %0.0
Hepatocellular carcinoma,9/51 %17.65,4/50 %8.0
Hepatic cancer metastatic,1/51 %1.96,0/50 %0.0
Hepatic encephalopathy,0/51 %0.0,1/50 %2.0
Haemorrhagic stroke,1/51 %1.96,0/50 %0.0
Renal failure,0/51 %0.0,1/50 %2.0
Pulmonary embolism,2/51 %3.92,0/50 %0.0
Bronchitis chronic,0/51 %0.0,1/50 %2.0
Skin ulcer,1/51 %1.96,0/50 %0.0

Sorafenib and TRC105 in Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT01306058)
 ,Sorafenib & TRC105 in Hepatocellular CA
 ,CA (cancer); 15 mg/kg TRC105 intravenous (IV) every 2 weeks and 400 mg sorafenib by mouth (PO) twice per day TRC 105: 15 mg/kg IV every 2 weeks Sorafenib: 400 mg twice a day (bid) continuously in a 28 days cycle
Total all-cause mortality,16/27 %59.26
Total serious adverse events,11/27 %40.74
Left ventricular systolic dysfunction,1/27 %3.7
Myocardial infarction,1/27 %3.7
Diarrhea,1/27 %3.7
Gastrointestinal pain,1/27 %3.7
Mucositis oral,1/27 %3.7
Pancreatitis,1/27 %3.7
Fever,1/27 %3.7
Infusion related reaction,1/27 %3.7
Hepatic failure,1/27 %3.7
Lung infection,1/27 %3.7
Sepsis,1/27 %3.7
Aspartate aminotransferase increased,1/27 %3.7
Blood bilirubin increased,1/27 %3.7
Lipase increased,1/27 %3.7
Serum amylase increased,1/27 %3.7
Intracranial hemorrhage,1/27 %3.7
Stroke,1/27 %3.7
Epistaxis,1/27 %3.7
Rash maculo-papular,2/27 %7.41
Flushing,1/27 %3.7
Hypotension,1/27 %3.7

A Phase II Trial of OSI-906 and Sorafenib in Advanced Hepatocellular Cancer(https://clinicaltrials.gov/show/NCT01334710)
 ,Sorafenib and OSI-906
 ,This is a single arm phase II trial designed to evaluate the effect of adding OSI-906 to sorafenib in patients with hepatocellular cancer. The study is designed to evaluate the safety of the regimen in the first six patients. Sorafenib and OSI-906 : Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
Total serious adverse events,0/3 %0.0

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia(https://clinicaltrials.gov/show/NCT01371981)
 ,Arm A,Arm B,Arm C (Cohort 1),Arm C (Cohort 2),Arm C (Cohort 3),Arm D
 ,INDUCTION (IND) 1Pts receive intrathecal (IT) cytarabine on day 1 and ADE with IV cytarabine over 1-30 minutes on days 1-10; daunorubicin hydrochloride IV over 1-15 minutes days1 3 5; etoposide IV 1-2 hours days1-5. IND IILow risk (LR) pts receive cytarabine IT and ADE chemotherapy as in INDI. High risk (HR) cytarabine IT day 1 MA chemo comprising high-dose cytarabine IV over 1-3 hours days1-4 mitoxantrone IV over 15-30 minutes days 3-6. INTENSIFICATION (INT) I: cytarabine IT day 1 AE chemo with high-dose cytarabine IV over 1-3 hours etoposide IV over 1-2 hours days 1-5. INT II: LR-cytarabine IT day 1; Induction II MA chemo. HR and no SCT donor - high-dose cytarabine IV over 3 hours days1 2 8 9; asparaginase intramuscularly (IM) days29. SCT: : pts receive fludarabine phosphate IV over 30 minutes once daily days -5 to -2 busulfan IV over 2 hours 4 times daily days -5 to -2. Allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis.,IND I: Pts receive cytarabine IT and ADE chemotherapy as in Induction I Arm A. Patients also receive bortezomib IV over 3-5 seconds on days 1 4 8. IND II: LR pts receive cytarabine IT ADE chemotherapy bortezomib as in IND I. HR pts receive cytarabine IT MA as in IND II Arm A (HR patients) and bortezomib IV on days 1 4 8. INT I: Pts receive cytarabine IT and AE in Arm A Intensification II and bortezomib IV on days 1 4 8. INT II: LR pts receive cytarabine IT on day 1 MA as in Arm A IND II (HR patients) and bortezomib IV on days 1 4 8. HR pts with no donor for SCT receive high-dose cytarabine IV over 3 hours on days 1 2 8 9 and asparaginase intramuscularly (IM) on days 2 and 9. SCT - Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily on days -5 to -2.Pts undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis.,IND II: Pts receive cytarabine IT on day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes on days 1 3 and 5 etoposide IV over 1-2 hours on days 1-5 sorafenib tosylate PO on days 9-36. INT I: Pts receive cytarabine IT and AE chemotherapy in Arm A Intensification II and sorafenib tosylate PO on daily on days 6-28. INT II: Pts receive cytarabine IT on day 1 MA chemotherapy as in Arm A Induction II (HR patients) sorafenib tosylate PO on days 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 busulfan IV over 2 hours 4 times daily on days -5 to -2. Patients undergo allogeneic SCT within 36 to 48 hours after the last dose of busulfan. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for one year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO at the time of known HR FLT3/ITD+ (including IND I & concurrently with chemo). IND II: Pts receive cytarabine IT day (d) 1 cytarabine IV over 1-30 minutes on d 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours d 1-5 sorafenib tosylate PO d 9-36. INTE I: Pts receive cytarabine IT and AE in Arm A INT II and sorafenib tosylate PO on daily d 6-28. INT II: Pts receive cytarabine IT on d 1 MA as in Arm A IND II (HR pts) sorafenib tosylate PO d 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on d -5 to -2 busulfan IV over 2 hours 4 times daily d -5 to -2. Pts undergo allogeneic SCT within 36-48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting d 40-100 after INT II or SCT for 1 year.,IND I: Pts receive cytarabine IT & ADE as in Arm A IND I & sorafenib tosylate PO days 11-28. IND II: Pts receive cytarabine IT day 1 cytarabine IV over 1-30 minutes on days 1-8 daunorubicin hydrochloride IV over 1-15 minutes days 1 3 5 etoposide IV over 1-2 hours days 1-5 sorafenib tosylate PO days 9-36. INT I: Pts receive cytarabine IT & AE cin Arm A INT II & sorafenib tosylate PO daily days 6-28. INT II: Pts receive cytarabine IT day 1 MA as in Arm A IND II (HR patients) & sorafenib tosylate PO days 7-34. SCT (HR patients with matched family [MFD] or unrelated donor): Pts receive fludarabine phosphate IV over 30 minutes once daily on days -5 to -2 and busulfan IV over 2 hours 4 times daily days -5 to -2. Pts undergo allogeneic SCT within 36 to 48 hours after last busulfan dose. Pts receive GVHD prophylaxis. MAINTENANCE: Pts receive sorafenib tosylate PO starting day 40-100 after INT II or SCT for 1 year.,INDUCTION I: Patients with unknown FLT3/ITD status prior to study enrollment receive cytarabine IT and ADE chemotherapy as in Arm A Induction I. If patients are determined to be HR FLT3/ITD+ no later than the end of Induction I they will be eligible to participate in Arm C.
Total all-cause mortality,198/559 %35.42,189/575 %32.87,7/12 %58.33,11/33 %33.33,16/47 %34.04,2/376 %0.53
Total serious adverse events,82/559 %14.67,305/575 %53.04,6/12 %50.0,16/33 %48.48,30/47 %63.83,2/376 %0.53
Anemia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Blood and lymphatic system disorders - Other specify,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bone marrow hypocellular,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Disseminated intravascular coagulation,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Febrile neutropenia,0/559 %0.0,21/575 %3.65,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hemolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hemolytic uremic syndrome,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Leukocytosis,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Asystole,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial fibrillation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atrial flutter,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac arrest,3/559 %0.54,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cardiac disorders - Other specify,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Chest pain - cardiac,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Heart failure,4/559 %0.72,15/575 %2.61,0/12 %0.0,1/33 %3.03,2/47 %4.26,0/376 %0.0
Left ventricular systolic dysfunction,3/559 %0.54,23/575 %4.0,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Myocardial infarction,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericardial effusion,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pericarditis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Restrictive cardiomyopathy,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Right ventricular dysfunction,2/559 %0.36,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus bradycardia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sinus tachycardia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Supraventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular arrhythmia,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular fibrillation,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ventricular tachycardia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adrenal insufficiency,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Endocrine disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothyroidism,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Eye disorders - Other specify,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Optic nerve disorder,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Papilledema,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Abdominal distension,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Abdominal pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anal pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ascites,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Colonic perforation,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Diarrhea,0/559 %0.0,9/575 %1.57,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Enterocolitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophagitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastric hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastritis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Gastrointestinal disorders - Other specify,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Ileus,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Lower gastrointestinal hemorrhage,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Mucositis oral,0/559 %0.0,3/575 %0.52,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nausea,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Oral pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pancreatitis,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Small intestinal obstruction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Typhlitis,2/559 %0.36,24/575 %4.17,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Upper gastrointestinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vomiting,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Chills,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Death NOS,38/559 %6.8,35/575 %6.09,1/12 %8.33,5/33 %15.15,6/47 %12.77,0/376 %0.0
Edema face,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fever,0/559 %0.0,13/575 %2.26,0/12 %0.0,0/33 %0.0,3/47 %6.38,0/376 %0.0
Gait disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypothermia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Multi-organ failure,1/559 %0.18,8/575 %1.39,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Non-cardiac chest pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bile duct stenosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cholecystitis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hepatic failure,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hepatobiliary disorders - Other specify,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Allergic reaction,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anaphylaxis,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Immune system disorders - Other specify,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anorectal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Appendicitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bladder infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchial infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Catheter related infection,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cecal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Duodenal infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalitis infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Enterocolitis infectious,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Esophageal infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Infections and infestations - Other specify,2/559 %0.36,13/575 %2.26,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lung infection,1/559 %0.18,13/575 %2.26,1/12 %8.33,2/33 %6.06,0/47 %0.0,0/376 %0.0
Lymph gland infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Meningitis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mucosal infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Periorbital infection,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sepsis,17/559 %3.04,50/575 %8.7,0/12 %0.0,1/33 %3.03,4/47 %8.51,0/376 %0.0
Skin infection,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Soft tissue infection,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheitis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Upper respiratory infection,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urinary tract infection,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Infusion related reaction,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Postoperative hemorrhage,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Vascular access complication,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Activated partial thromboplastin time prolonged,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Alanine aminotransferase increased,0/559 %0.0,16/575 %2.78,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Aspartate aminotransferase increased,1/559 %0.18,10/575 %1.74,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Blood bilirubin increased,2/559 %0.36,16/575 %2.78,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Carbon monoxide diffusing capacity decreased,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Creatinine increased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Ejection fraction decreased,2/559 %0.36,18/575 %3.13,0/12 %0.0,2/33 %6.06,4/47 %8.51,0/376 %0.0
Electrocardiogram QT corrected interval prolonged,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Fibrinogen decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
GGT increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Investigations - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Lipase increased,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Lymphocyte count decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neutrophil count decreased,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Platelet count decreased,0/559 %0.0,7/575 %1.22,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Serum amylase increased,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urine output decreased,1/559 %0.18,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Weight loss,0/559 %0.0,0/575 %0.0,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
White blood cell decreased,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acidosis,0/559 %0.0,4/575 %0.7,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Alkalosis,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Anorexia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Dehydration,0/559 %0.0,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypercalcemia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperglycemia,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyperkalemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypernatremia,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Hypertriglyceridemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypoalbuminemia,0/559 %0.0,6/575 %1.04,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypocalcemia,0/559 %0.0,8/575 %1.39,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypokalemia,1/559 %0.18,27/575 %4.7,0/12 %0.0,2/33 %6.06,1/47 %2.13,0/376 %0.0
Hypomagnesemia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hyponatremia,0/559 %0.0,10/575 %1.74,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypophosphatemia,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Metabolism and nutrition disorders - Other specify,2/559 %0.36,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tumor lysis syndrome,1/559 %0.18,3/575 %0.52,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Arthralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Back pain,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neck pain,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain in extremity,0/559 %0.0,2/575 %0.35,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,2/559 %0.36,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Ataxia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Central nervous system necrosis,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cerebrospinal fluid leakage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cognitive disturbance,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Depressed level of consciousness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dizziness,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dysesthesia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Edema cerebral,1/559 %0.18,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Encephalopathy,1/559 %0.18,5/575 %0.87,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Headache,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hydrocephalus,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypersomnia,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Intracranial hemorrhage,2/559 %0.36,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,1/376 %0.27
Leukoencephalopathy,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Nervous system disorders - Other specify,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Neuralgia,0/559 %0.0,1/575 %0.17,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Paresthesia,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Peripheral sensory neuropathy,0/559 %0.0,14/575 %2.43,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Reversible posterior leukoencephalopathy syndrome,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Seizure,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Somnolence,0/559 %0.0,4/575 %0.7,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Syncope,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Agitation,0/559 %0.0,2/575 %0.35,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Anxiety,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Delirium,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Acute kidney injury,5/559 %0.89,15/575 %2.61,0/12 %0.0,3/33 %9.09,3/47 %6.38,0/376 %0.0
Cystitis noninfective,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hematuria,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Proteinuria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Renal and urinary disorders - Other specify,1/559 %0.18,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Adult respiratory distress syndrome,3/559 %0.54,15/575 %2.61,0/12 %0.0,2/33 %6.06,0/47 %0.0,0/376 %0.0
Apnea,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Aspiration,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Atelectasis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchopulmonary hemorrhage,3/559 %0.54,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Bronchospasm,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Cough,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Dyspnea,1/559 %0.18,12/575 %2.09,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Epistaxis,0/559 %0.0,7/575 %1.22,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Hypoxia,3/559 %0.54,55/575 %9.57,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Laryngeal edema,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Laryngeal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Mediastinal hemorrhage,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pharyngeal mucositis,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pleural effusion,0/559 %0.0,8/575 %1.39,0/12 %0.0,1/33 %3.03,0/47 %0.0,0/376 %0.0
Pneumonitis,0/559 %0.0,9/575 %1.57,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Productive cough,0/559 %0.0,0/575 %0.0,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Pulmonary edema,3/559 %0.54,12/575 %2.09,0/12 %0.0,0/33 %0.0,2/47 %4.26,0/376 %0.0
Pulmonary hypertension,1/559 %0.18,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Respiratory failure,10/559 %1.79,22/575 %3.83,0/12 %0.0,2/33 %6.06,2/47 %4.26,0/376 %0.0
Respiratory thoracic and mediastinal disorders - Other specify,1/559 %0.18,6/575 %1.04,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Sore throat,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Stridor,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Tracheal mucositis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Wheezing,0/559 %0.0,3/575 %0.52,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Erythroderma,0/559 %0.0,0/575 %0.0,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Pain of skin,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Palmar-plantar erythrodysesthesia syndrome,0/559 %0.0,1/575 %0.17,1/12 %8.33,1/33 %3.03,1/47 %2.13,0/376 %0.0
Pruritus,0/559 %0.0,1/575 %0.17,1/12 %8.33,0/33 %0.0,0/47 %0.0,0/376 %0.0
Rash maculo-papular,0/559 %0.0,10/575 %1.74,1/12 %8.33,2/33 %6.06,3/47 %6.38,0/376 %0.0
Skin and subcutaneous tissue disorders - Other specify,0/559 %0.0,2/575 %0.35,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Toxic epidermal necrolysis,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Urticaria,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Capillary leak syndrome,0/559 %0.0,5/575 %0.87,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0
Flushing,0/559 %0.0,1/575 %0.17,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Hypertension,0/559 %0.0,10/575 %1.74,0/12 %0.0,1/33 %3.03,1/47 %2.13,0/376 %0.0
Hypotension,7/559 %1.25,47/575 %8.17,1/12 %8.33,3/33 %9.09,3/47 %6.38,0/376 %0.0
Peripheral ischemia,1/559 %0.18,0/575 %0.0,0/12 %0.0,0/33 %0.0,0/47 %0.0,0/376 %0.0
Thromboembolic event,3/559 %0.54,3/575 %0.52,0/12 %0.0,0/33 %0.0,1/47 %2.13,0/376 %0.0

TRC105 for Liver Cancer That Has Not Responded to Sorafenib(https://clinicaltrials.gov/show/NCT01375569)
 ,TRC105 in Liver Cancer
 ,TRC105 is an experimental cancer drug designed to slow or stop the growth of tumors. It does this by preventing the growth of new blood vessels that feed these tumors. This drug is being used to test the safety and effectiveness to treat liver cancer that has not responded to standard therapy. TRC105 will be given as an intravenous infusion every two weeks.
Total all-cause mortality,0/11 %0.0
Total serious adverse events,5/11 %45.45
Myocardial infarction,1/11 %9.09
Hepatic failure,1/11 %9.09
Lung infection,1/11 %9.09
Aspartate aminotransferase increased,1/11 %9.09
Neoplasms benign malignant and unspecified (incl cysts and polyps) - Other specify,1/11 %9.09
Encephalopathy,1/11 %9.09

Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer(https://clinicaltrials.gov/show/NCT01471353)
 ,Sorafenib Plus Capecitabine (SorCape)
 ,Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days. Single arm study. Sorafenib Plus Capecitabine (SorCape): Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
Total serious adverse events,13/42 %30.95
Anemia,1/42 %2.38
Spleen Disorder,1/42 %2.38
Sinus Tachycardia,1/42 %2.38
Abdominal Pain,2/42 %4.76
Colonic Obstruction,1/42 %2.38
Gastrointestinal Disorders - Other Bowel Perforation,1/42 %2.38
Fatigue,1/42 %2.38
General Disorders and Administration Site Conditions - Other Anasarca,1/42 %2.38
Non-Cardiac Chest Pain,2/42 %4.76
Pain,1/42 %2.38
Hepatobiliary Disorders - Other Cirrhosis,1/42 %2.38
Sepsis,1/42 %2.38
Creatinine Increased,1/42 %2.38
Hyponatremia,1/42 %2.38
Dehydration,2/42 %4.76
Generalized Muscle Weakness,1/42 %2.38
Syncope,1/42 %2.38
Agitation,1/42 %2.38
Confusion,1/42 %2.38
Delirium,2/42 %4.76
Pneumothorax,1/42 %2.38

MEDI-573 in Combination With SOC in Unresectable or Metastatic HCC.(https://clinicaltrials.gov/show/NCT01498952)
 ,Phase 1b Cohort A,Phase 1b Cohort B
 ,Participants received MEDI-573 10 mg/kg IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity documentation of disease progression initiation of alternative anticancer treatment or withdrawal for other reasons.,Participants received MEDI-573 45 mg/kg IV on Day 1 of each 21-day cycle and sorafenib 400 mg orally twice daily as background therapy until unacceptable toxicity documentation of disease progression initiation of alternative anticancer treatment or withdrawal for other reasons.
Total all-cause mortality,2/3 %66.67,2/3 %66.67
Total serious adverse events,1/3 %33.33,1/3 %33.33
Abdominal pain,1/3 %33.33,0/3 %0.0
Asthenia,1/3 %33.33,0/3 %0.0
Non-cardiac chest pain,1/3 %33.33,0/3 %0.0
Hepatic failure,0/3 %0.0,1/3 %33.33
Lipase increased,0/3 %0.0,1/3 %33.33
Hepatic encephalopathy,0/3 %0.0,1/3 %33.33
Pneumothorax,1/3 %33.33,0/3 %0.0

Sorafenib for the Treatment of Chronic Lymphocytic Leukemia (CLL)(https://clinicaltrials.gov/show/NCT01510756)
 ,Sorafenib
 ,Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Sorafenib: Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
Total serious adverse events,1/4 %25.0
Brain abscess (aspergillus),1/4 %25.0

Phase I/II Study of Combination of Sorafenib  Vorinostat  and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype(https://clinicaltrials.gov/show/NCT01534260)
 ,Phase I Dose Escalating,Phase II at MTD
 ,escalating dose cohorts of sorafenib vorinostat and bortezomib. All cohorts will receive sorafenib from day 1 to 14 and vorinostat from day 1 to 4 and day 8 to 12. Bortezomib will be given on days 1 and 8 for all cohorts with cohorts 4 and 5 also receiving bortezomib on days 4 and 11 for cycles 1 through 4. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.,patients received sorafenib at 400 mg bid from day 1 to 14 and vorinostat 200 mg bid from day 1 to 14. Bortezomib will be given at 1.3 mg/m2 on days 1 4 8 and 11 for cycles 1-4 and then on days 1 and 8 for cycle 5 and beyond. Bortezomib will be given on days 1 and 8 beyond 4 cycles to reduce the risk of neurotoxicity.
Total serious adverse events,7/17 %41.18,11/20 %55.0
Febrile neutropenia,2/17 %11.76,1/20 %5.0
Myocardial infarction,0/17 %0.0,1/20 %5.0
Eye disorders  Other,0/17 %0.0,1/20 %5.0
Diarrhea,0/17 %0.0,2/20 %10.0
Nausea,1/17 %5.88,0/20 %0.0
Rectal hemorrhage,1/17 %5.88,0/20 %0.0
Fever,3/17 %17.65,2/20 %10.0
Lung infection,1/17 %5.88,1/20 %5.0
Sepsis,1/17 %5.88,2/20 %10.0
Neutrophil count decreased,0/17 %0.0,1/20 %5.0
Generalized muscle weakness,0/17 %0.0,1/20 %5.0
Myositis,0/17 %0.0,1/20 %5.0
Syncope,0/17 %0.0,1/20 %5.0
Epistaxis,1/17 %5.88,0/20 %0.0
Respiratory failure,0/17 %0.0,2/20 %10.0

Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate(https://clinicaltrials.gov/show/NCT01582009)
 ,Arm I: Oral Panobinostat and Oral Everolimus
 ,Patients receive oral panobinostat once daily on days 1 3 4 8 10 and 12 and oral everolimus once daily on days 1-21. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity. panobinostat: Given orally everolimus: Given orally laboratory biomarker analysis: Correlative studies pharmacological study: Correlative studies liquid chromatography: Correlative studies mass spectrometry: Correlative studies enzyme-linked immunosorbent assay: Correlative studies immunohistochemistry staining method: Correlative studies
Total serious adverse events,9/26 %34.62
Thrombocytopenia,1/26 %3.85
Atrial fibrillation,1/26 %3.85
Supraventricular tachycardia,1/26 %3.85
Abdominal hernia,1/26 %3.85
Abdominal pain lower,1/26 %3.85
Disease progression,1/26 %3.85
Pneumocystis jiroveci pneumonia,1/26 %3.85
Pneumonia,1/26 %3.85
Contusion,1/26 %3.85
Dehydration,1/26 %3.85
Muscular weakness,1/26 %3.85
Confusional state,1/26 %3.85
Dyspnoea,1/26 %3.85

SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)(https://clinicaltrials.gov/show/NCT01752933)
 ,Guadecitabine 60 mg/m^2,Guadecitabine 45 mg/m^2
 ,Guadecitabine (SGI-110) 60 mg/m^2 SC on Days 1 - 5 of each 28-day cycle,Guadecitabine (SGI-110) 45 mg/m^2 SC on Days 1 - 5 of each 28-day cycle
Total all-cause mortality,4/4 %100.0,34/46 %73.91
Total serious adverse events,1/4 %25.0,21/46 %45.65
Anaemia,0/4 %0.0,1/46 %2.17
Febrile neutropenia,1/4 %25.0,5/46 %10.87
Atrial fibrillation,0/4 %0.0,1/46 %2.17
Adrenal haemorrhage,0/4 %0.0,1/46 %2.17
Abdominal pain,0/4 %0.0,2/46 %4.35
Ascites,0/4 %0.0,1/46 %2.17
Diarrhoea,0/4 %0.0,1/46 %2.17
Gastrointestinal haemorrhage,0/4 %0.0,1/46 %2.17
Nausea,0/4 %0.0,1/46 %2.17
Oesophagitis,0/4 %0.0,1/46 %2.17
Upper gastrointestinal haemorrhage,0/4 %0.0,1/46 %2.17
Vomiting,0/4 %0.0,1/46 %2.17
Hyperbilirubinaemia,0/4 %0.0,1/46 %2.17
Portal vein thrombosis,0/4 %0.0,1/46 %2.17
Pneumonia,0/4 %0.0,1/46 %2.17
Staphylococcal sepsis,0/4 %0.0,1/46 %2.17
Road traffic accident,0/4 %0.0,2/46 %4.35
Blood creatinine increased,0/4 %0.0,1/46 %2.17
Hyponatremia,0/4 %0.0,1/46 %2.17
Pain in extremity,0/4 %0.0,2/46 %4.35
Hepatic encephalopathy,0/4 %0.0,1/46 %2.17
Nephrolithiasis,0/4 %0.0,1/46 %2.17
Renal failure acute,0/4 %0.0,1/46 %2.17
Scrotal pain,0/4 %0.0,1/46 %2.17
Hypoxia,0/4 %0.0,1/46 %2.17
Respiratory failure,0/4 %0.0,1/46 %2.17
Hypotension,0/4 %0.0,1/46 %2.17

A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective(https://clinicaltrials.gov/show/NCT01754987)
 ,Ascorbic Acid + Sorafenib,Sorafenib Alone
 ,Drug: Vitamin C Other Names: Ascorbic Acid Ascorbate Dosage: Vitamin C : 100 grams (infusion) Phase I: 3x a week for 8 weeks Phase II: 3x a week for 16 weeks Sorafenib: taken daily (oral) Ascorbic Acid + Sorafenib,Sorafenib: taken daily (oral) Sorafenib
Total serious adverse events,1/5 %20.0,0/0 %0.0
Dehydration,1/5 %20.0,0/0 %0.0

Sorafenib + mFOLFOX for Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01775501)
 ,FOLFOX + Sorafenib
 ,FOLFOX (Leucovorin Fluorouracil and Oxaliplatin) + Sorafenib Sorafenib: orally twice daily FOLFOX: injected via portacath once every two weeks Leucovorin: 200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Fluorouracil: 5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Oxaliplatin: 85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops. Sorafenib: 400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Total all-cause mortality,2/40 %5.0
Total serious adverse events,32/40 %80.0
Anemia,3/40 %7.5
Bleeding (Epistaxis Hematuria Hematoma Hemorrhoidal hemorrhage Rectal hemorrhage),1/40 %2.5
Diarrhea,4/40 %10.0
Mouth Sores,1/40 %2.5
Pancreatitis,1/40 %2.5
Fatigue,3/40 %7.5
Fever,1/40 %2.5
Vascular access complication,1/40 %2.5
Alanine aminotransferase increased,6/40 %15.0
Alkaline phosphatase increased,2/40 %5.0
Aspartate aminotransferase increased,9/40 %22.5
Blood bilirubin increased,4/40 %10.0
Lipase increased,9/40 %22.5
Lymphocyte count decreased,7/40 %17.5
Neutrophil count decreased,3/40 %7.5
Platelet count decreased,2/40 %5.0
Serum amylase increased,2/40 %5.0
Hyperglycemia,1/40 %2.5
Hypernatremia,1/40 %2.5
Hyponatremia,2/40 %5.0
Hypophosphatemia,13/40 %32.5
Pneumonitis,1/40 %2.5
Diaphoresis,1/40 %2.5
Palmar-plantar erythrodysesthesia syndrome,3/40 %7.5
Rash,1/40 %2.5
Flushing,1/40 %2.5
Hypertension,2/40 %5.0

Efficacy Evaluation of TheraSphere to Treat Inoperable Liver Cancer With Blockage of the Portal Vein(https://clinicaltrials.gov/show/NCT01887717)
 ,TheraSphere,Sorafenib
 ,Participants received TheraSphere at a dose consistent with the approved package insert to the treated lobe of the liver. TheraSphere was administered through the hepatic artery. The targeted dose was 120 Gy + 10%. Dose reduction to a minimum dose of 80 Gy + 10% was permitted to manage radiation exposure to the lungs. Re-treatment of the same participant/lobe with further cycles of TheraSphere was permitted if a treatable progression was detected during follow-up evaluations. Any re-treatment took place at least 28 days after the previous TheraSphere treatment administered to that lobe. Participants could receive a subsequent TheraSphere administration in the absence of radiological progression criteria at the Investigator's discretion. A maximum of 3 TheraSphere administrations was permitted.,Participants received sorafenib oral tablets 400 milligrams (mg) twice daily in accordance with the package insert. Treatment was to continue until the participant was no longer clinically benefiting from therapy or until unacceptable toxicity occurred. Medically appropriate dose adjustments and drug holidays due to adverse events (AEs) and toxicity were allowed.
Total all-cause mortality,15/15 %100.0,16/16 %100.0
Total serious adverse events,0/15 %0.0,12/16 %75.0
Diarrhoea,0/15 %0.0,1/16 %6.25
Gastrointestinal haemorrhage,0/15 %0.0,1/16 %6.25
Gastrointestinal vascular malformation,0/15 %0.0,1/16 %6.25
Haematemesis,0/15 %0.0,1/16 %6.25
Nausea,0/15 %0.0,1/16 %6.25
Vomiting,0/15 %0.0,1/16 %6.25
General Physical Health Deterioration,0/15 %0.0,1/16 %6.25
Influenza like illness,0/15 %0.0,1/16 %6.25
Hepatic encephalopathy,0/15 %0.0,2/16 %12.5
Dyspnoea,0/15 %0.0,1/16 %6.25
Respiratory Failure,0/15 %0.0,1/16 %6.25

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer(https://clinicaltrials.gov/show/NCT01911273)
 ,PF-03446962 Plus BSC,BSC Alone
 ,PF-03446962 7 mg/kg was administered IV as 1-hour infusion q2w plus BSC,BSC might vary depending on the participant's signs and symptoms site current practice and country practice and might include medications and supportive measures deemed necessary to palliate disease-related symptoms and improve quality of life.
Total serious adverse events,0/1 %0.0,0/2 %0.0

Efficacy  Safety  and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT01988493)
 ,Phase 1b: Tepotinib 300 mg,Phase 1b: Tepotinib 500 mg,Phase 1b: Tepotinib 1000 mg,Phase 2: Tepotinib,Phase 2 Sorafenib
 ,Participants received Tepotinib 300 milligram (mg) orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants received Tepotinib 500 mg orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants received Tepotinib 1000 mg orally once daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants randomized to receive Tepotinib recommended Phase 2 dose (RP2D) determined from Phase 1b over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.,Participants randomized to receive Sorafenib 400 mg orally twice daily over a 21-day cycle until disease progression intolerable toxicity or participant withdrawal.
Total all-cause mortality,7/7 %100.0,11/14 %78.57,3/6 %50.0,24/45 %53.33,30/44 %68.18
Total serious adverse events,2/7 %28.57,9/14 %64.29,4/6 %66.67,23/45 %51.11,12/44 %27.27
Thrombocytopenia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Supraventricular tachycardia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Abdominal pain,0/7 %0.0,1/14 %7.14,1/6 %16.67,2/45 %4.44,2/44 %4.55
Ascites,0/7 %0.0,1/14 %7.14,0/6 %0.0,2/45 %4.44,0/44 %0.0
Diarrhoea,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,1/44 %2.27
Duodenal ulcer,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Encapsulating peritoneal sclerosis,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Ileus,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,0/44 %0.0
Melaena,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Upper gastrointestinal haemorrhage,0/7 %0.0,1/14 %7.14,0/6 %0.0,1/45 %2.22,1/44 %2.27
Duodenal ulcer haemorrhage,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Peritoneal haemorrhage,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Disease progression,1/7 %14.29,0/14 %0.0,0/6 %0.0,7/45 %15.56,2/44 %4.55
Asthenia,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hernia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Oedema peripheral,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,0/44 %0.0
Cholecystitis acute,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hepatic failure,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,1/44 %2.27
Hepatic function abnormal,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Candida infection,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Cellulitis,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Enteritis infectious,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Pneumonia,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Alanine aminotransferase increased,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Aspartate aminotransferase increased,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Blood bilirubin increased,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,1/44 %2.27
Lipase increased,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Decreased appetite,0/7 %0.0,0/14 %0.0,1/6 %16.67,1/45 %2.22,0/44 %0.0
Hyperglycaemia,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Muscular weakness,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Musculoskeletal pain,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Gouty arthritis,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0
Metastases to central nervous system,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Bladder cancer,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Cerebrovascular accident,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Haemorrhage intracranial,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hepatic encephalopathy,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,1/44 %2.27
Paraesthesia,0/7 %0.0,0/14 %0.0,0/6 %0.0,2/45 %4.44,0/44 %0.0
Seizure,0/7 %0.0,0/14 %0.0,1/6 %16.67,0/45 %0.0,0/44 %0.0
Dyspnoea exertional,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Haemoptysis,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Pleural effusion,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Rash maculo-papular,0/7 %0.0,1/14 %7.14,0/6 %0.0,0/45 %0.0,0/44 %0.0
Deep vein thrombosis,0/7 %0.0,0/14 %0.0,0/6 %0.0,0/45 %0.0,1/44 %2.27
Hypertension,1/7 %14.29,0/14 %0.0,0/6 %0.0,0/45 %0.0,0/44 %0.0
Lymphoedema,0/7 %0.0,0/14 %0.0,0/6 %0.0,1/45 %2.22,0/44 %0.0

Sorafenib Tosylate  Combination Chemotherapy  Radiation Therapy  and Surgery in Treating Patients With High-Risk Stage IIB-IV Soft Tissue Sarcoma(https://clinicaltrials.gov/show/NCT02050919)
 ,Treatment (Sorafenib Chemotherapy Radiation Surgery)
 ,Patients receive sorafenib tosylate PO QD on days 1-71 and 85-155 epirubicin hydrochloride IV over 3-5 minutes and ifosfamide IV over 90 minutes on days 15-17 36-38 (ifosfamide only) 57-59 99-101 120-122 and 141-143. Patients undergo EBRT on days 36-45 and surgical resection on day 78. Patients with positive margins undergo EBRT boost on days 91-98. Epirubicin Hydrochloride: Given IV External Beam Radiation Therapy: Undergo EBRT Ifosfamide: Given IV Laboratory Biomarker Analysis: Correlative studies Sorafenib Tosylate: Given PO Therapeutic Conventional Surgery: Undergo surgical resection
Total all-cause mortality,5/20 %25.0
Total serious adverse events,18/20 %90.0
Febrile Neutropenia,12/20 %60.0
Constipation,1/20 %5.0
Diarrhea,1/20 %5.0
Catheter Related infection,1/20 %5.0
enterocolitis infectious,1/20 %5.0
Sepsis,3/20 %15.0
Soft tissue infection,1/20 %5.0
wound infection,7/20 %35.0
wound dehiscence,1/20 %5.0
Lymphocyte count decreased,1/20 %5.0
Neutrophil Count decreased,1/20 %5.0
Platelet Count Decreased,2/20 %10.0
Hypokalemia,1/20 %5.0
Encephalopathy,3/20 %15.0
syncope,1/20 %5.0
Delirium,1/20 %5.0
Palmar-plantar erythrodysesthesia syndrome,1/20 %5.0

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis(https://clinicaltrials.gov/show/NCT02066181)
 ,Arm I (Sorafenib Tosylate),Arm II (Placebo),Crossover Group
 ,Patients receive sorafenib tosylate PO QD on days 1-28.,Patients receive placebo PO QD on days 1-28. Patients may crossover to Arm I upon disease progression.,Upon disease progression patients treated with placebo will be allowed to crossover to the open label sorafenib arm.
Total all-cause mortality,1/49 %2.04,0/36 %0.0,0/28 %0.0
Total serious adverse events,11/49 %22.45,6/36 %16.67,5/28 %17.86
Anemia,1/49 %2.04,0/36 %0.0,0/28 %0.0
Blood and lymphatic system disorders - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Chest pain - cardiac,1/49 %2.04,0/36 %0.0,0/28 %0.0
Heart failure,1/49 %2.04,0/36 %0.0,0/28 %0.0
Palpitations,1/49 %2.04,0/36 %0.0,0/28 %0.0
Abdominal pain,0/49 %0.0,1/36 %2.78,0/28 %0.0
Diarrhea,2/49 %4.08,0/36 %0.0,0/28 %0.0
Gastric perforation,1/49 %2.04,0/36 %0.0,0/28 %0.0
Malabsorption,0/49 %0.0,0/36 %0.0,1/28 %3.57
Nausea,1/49 %2.04,1/36 %2.78,0/28 %0.0
Pancreatitis,1/49 %2.04,0/36 %0.0,0/28 %0.0
Small intestinal obstruction,0/49 %0.0,2/36 %5.56,0/28 %0.0
Vomiting,0/49 %0.0,1/36 %2.78,0/28 %0.0
Fatigue,2/49 %4.08,0/36 %0.0,0/28 %0.0
Fever,0/49 %0.0,1/36 %2.78,0/28 %0.0
General disorders and administration site conditions - Other specify,0/49 %0.0,1/36 %2.78,0/28 %0.0
Appendicitis,0/49 %0.0,0/36 %0.0,1/28 %3.57
Sepsis,0/49 %0.0,0/36 %0.0,1/28 %3.57
Injury poisoning and procedural complications - Other specify,0/49 %0.0,0/36 %0.0,1/28 %3.57
Alanine aminotransferase increased,0/49 %0.0,0/36 %0.0,1/28 %3.57
Hypertriglyceridemia,1/49 %2.04,1/36 %2.78,0/28 %0.0
Arthralgia,1/49 %2.04,0/36 %0.0,0/28 %0.0
Flank pain,0/49 %0.0,1/36 %2.78,0/28 %0.0
Pregnancy puerperium and perinatal conditions - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Unintended pregnancy,1/49 %2.04,0/36 %0.0,0/28 %0.0
Acute kidney injury,1/49 %2.04,0/36 %0.0,0/28 %0.0
Dyspnea,1/49 %2.04,0/36 %0.0,0/28 %0.0
Palmar-plantar erythrodysesthesia syndrome,2/49 %4.08,0/36 %0.0,0/28 %0.0
Skin and subcutaneous tissue disorders - Other specify,1/49 %2.04,0/36 %0.0,0/28 %0.0
Hypertension,1/49 %2.04,1/36 %2.78,1/28 %3.57

c-Met Second-Line Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02115373)
 ,Phase 1b: Tepotinib 300 mg,Phase 1b: Tepotinib 500 mg,Phase 2: Tepotinib 500 mg
 ,Participants received a single oral dose of Tepotinib 300 milligram (mg) daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.,Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.,Participants received a single oral dose of Tepotinib 500 mg daily in each 21 days treatment cycle until progressive disease intolerable toxicity death or withdrawal from treatment.
Total all-cause mortality,3/4 %75.0,11/13 %84.62,40/49 %81.63
Total serious adverse events,2/4 %50.0,5/13 %38.46,21/49 %42.86
Abdominal pain,1/4 %25.0,0/13 %0.0,0/49 %0.0
Ascites,0/4 %0.0,2/13 %15.38,3/49 %6.12
Gastrointestinal haemorrhage,0/4 %0.0,0/13 %0.0,1/49 %2.04
Disease progression,1/4 %25.0,1/13 %7.69,7/49 %14.29
Localised oedema,0/4 %0.0,1/13 %7.69,0/49 %0.0
Oedema peripheral,0/4 %0.0,2/13 %15.38,1/49 %2.04
Discomfort,0/4 %0.0,0/13 %0.0,1/49 %2.04
General physical health deterioration,0/4 %0.0,0/13 %0.0,1/49 %2.04
Pyrexia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Vascular stent stenosis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Cholangitis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hepatic failure,0/4 %0.0,0/13 %0.0,1/49 %2.04
Jaundice,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hepatorenal syndrome,0/4 %0.0,1/13 %7.69,0/49 %0.0
Device related infection,0/4 %0.0,0/13 %0.0,1/49 %2.04
Peritonitis bacterial,0/4 %0.0,0/13 %0.0,1/49 %2.04
Sepsis,0/4 %0.0,1/13 %7.69,1/49 %2.04
Peritonitis,0/4 %0.0,1/13 %7.69,0/49 %0.0
Post procedural infection,1/4 %25.0,0/13 %0.0,0/49 %0.0
Blood bilirubin increased,1/4 %25.0,0/13 %0.0,0/49 %0.0
Hypercalcaemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hypercreatininaemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hyponatraemia,0/4 %0.0,0/13 %0.0,1/49 %2.04
Decreased appetite,1/4 %25.0,0/13 %0.0,0/49 %0.0
Rhabdomyolysis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Cancer pain,0/4 %0.0,0/13 %0.0,1/49 %2.04
Tumour pain,0/4 %0.0,0/13 %0.0,1/49 %2.04
Coma,0/4 %0.0,1/13 %7.69,0/49 %0.0
Hepatic encephalopathy,0/4 %0.0,1/13 %7.69,0/49 %0.0
Cerebral thrombosis,0/4 %0.0,0/13 %0.0,1/49 %2.04
Hypoglycaemic coma,0/4 %0.0,0/13 %0.0,1/49 %2.04
Acute kidney injury,1/4 %25.0,1/13 %7.69,3/49 %6.12
Chronic kidney disease,0/4 %0.0,0/13 %0.0,1/49 %2.04
Prostatitis,0/4 %0.0,1/13 %7.69,0/49 %0.0
Pneumonia aspiration,0/4 %0.0,0/13 %0.0,1/49 %2.04

Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation(https://clinicaltrials.gov/show/NCT02196857)
 ,Azacytidine + Sorafenib
 ,Azacitidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) daily for 7 days per 28 day cycle. Sorafenib administered orally at a dose of 400 mg twice daily every day continuously. Azacytidine: 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle. Sorafenib: 400 mg by mouth twice daily about 12 hours apart every day for a 28 day cycle.
Total all-cause mortality,0/16 %0.0
Total serious adverse events,14/16 %87.5
Cardiac Triponin Increase,1/16 %6.25
Intracranial Hemorrhage,1/16 %6.25
Thrombocytopenia,1/16 %6.25
Acute Heart Failure,1/16 %6.25
Colitis,2/16 %12.5
Dehydration,1/16 %6.25
Intestine Obstruction,1/16 %6.25
Facial Pain/Dental,1/16 %6.25
Fatigue,1/16 %6.25
Fever,1/16 %6.25
Cellulitis,1/16 %6.25
Febrile Neutropenia,5/16 %31.25
Urinary Tract Infection,2/16 %12.5
Infection,1/16 %6.25
Lung Infection,5/16 %31.25
Sepsis,1/16 %6.25
Skin Infection,1/16 %6.25
Arthritis,1/16 %6.25
Seizure,1/16 %6.25
Stroke,1/16 %6.25
Syncope,1/16 %6.25
Tremor,1/16 %6.25
Acute Kidney failure,1/16 %6.25
generalized edema,1/16 %6.25
Acute Respiratory Failure,1/16 %6.25
Dyspnea,2/16 %12.5
Laryngeal Hemorrhage,1/16 %6.25
Laryngeal Inflammation,2/16 %12.5
Hypotnesion,4/16 %25.0

A Study of ONCO-DOX in Locally Advanced Hepatocellular Carcinoma(https://clinicaltrials.gov/show/NCT02460991)
 ,DEB-TACE,Sorafenib
 ,ONCO-DOX (Doxorubicin loaded Microspheres) up to 150 mg per treatment; treatments could be repeated every 4-8 weeks until complete tumor response was achieved,200 mg of Sorafenib twice daily; continue until unacceptable toxicity or unequivocal tumor progression
Total all-cause mortality,0/0 %0.0,0/2 %0.0
Total serious adverse events,0/0 %0.0,1/2 %50.0
Hypertensive Emergency,0/0 %0.0,1/2 %50.0
